<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003429.pub3" GROUP_ID="CF" ID="855601070415501941" MERGED_FROM="" MODIFIED="2011-07-20 15:08:00 +0200" MODIFIED_BY="Tracey Remmington" REVIEW_NO="0044" REVMAN_SUB_VERSION="5.1.2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2011-07-20 09:20:47 +0100" MODIFIED_BY="Tracey Remmington">
<TITLE>Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B</TITLE>
<CONTACT>
<PERSON ID="11708" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alfonso</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Iorio</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>iorioa@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+12893393713</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Clinical Epidemiology and Biostatistic Department</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1280 Main Street West</ADDRESS_1>
<ADDRESS_2>CRL - 140</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8S 4K1</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 525 9140 ext 22421</PHONE_1>
<PHONE_2>+1 289 339 3713</PHONE_2>
<FAX_1>+1 905-526-8447</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-07-20 09:20:47 +0100" MODIFIED_BY="Tracey Remmington">
<PERSON ID="11708" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alfonso</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Iorio</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>iorioa@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+12893393713</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Clinical Epidemiology and Biostatistic Department</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1280 Main Street West</ADDRESS_1>
<ADDRESS_2>CRL - 140</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8S 4K1</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 525 9140 ext 22421</PHONE_1>
<PHONE_2>+1 289 339 3713</PHONE_2>
<FAX_1>+1 905-526-8447</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B5396B7182E26AA2004F1ADAE72B5EF4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Emanuela</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Marchesini</LAST_NAME>
<SUFFIX/>
<POSITION>Internal and Vascular Medicine - Hemophilia Centre</POSITION>
<EMAIL_1>manumarchesini@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1>Ospedale Santa Maria della Misericordia</ADDRESS_1>
<ADDRESS_2>Località Sant'Andrea delle Fratte</ADDRESS_2>
<CITY>Perugia</CITY>
<ZIP>06126</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="EC79191F82E26AA201905335717A8EF3" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Marcucci</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>marcucci.maura@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+39 3280344384</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1>G. Dottori, 1</ADDRESS_1>
<ADDRESS_2/>
<CITY>Perugia</CITY>
<ZIP>06100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 075 5782309</PHONE_1>
<PHONE_2/>
<FAX_1>+39 075 5782309</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11812" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Kent</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Stobart</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Pediatrics</POSITION>
<EMAIL_1>kent.stobart@albertahealthservices.ca</EMAIL_1>
<EMAIL_2>kent.stobart@ualberta.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Northern Alberta Children's Cancer Program, Department of Pediatrics</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>Room 7327A Aberhart Centre</ADDRESS_1>
<ADDRESS_2>11402 University Avenue NW</ADDRESS_2>
<CITY>Edmonton</CITY>
<ZIP>T6G 2J3</ZIP>
<REGION>Alberta</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 407 8829</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407 7136</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="58306295358236654920100426093828" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS>KC</MIDDLE_INITIALS>
<LAST_NAME>Chan</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Pediatrics</POSITION>
<EMAIL_1>akchan@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Pediatric Hematology/Oncology, Health Sciences Centre</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1200 Main Street West</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hamilton</CITY>
<ZIP>L8N 3Z5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 521 2100 Ext: 73464</PHONE_1>
<PHONE_2/>
<FAX_1>+1 905 521 1703</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-07-10 13:36:12 +0100" MODIFIED_BY="Alfonso Iorio">
<UP_TO_DATE>
<DATE DAY="10" MONTH="7" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="4" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="7" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2011-07-10 16:36:29 +0100" MODIFIED_BY="Alfonso Iorio">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-07-10 13:37:04 +0100" MODIFIED_BY="Alfonso Iorio">
<DATE DAY="10" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Two new trials have been incorporated into the review (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-07-10 16:36:29 +0100" MODIFIED_BY="Alfonso Iorio">
<DATE DAY="10" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>The conclusions of the review have changed from there being insufficient evidence assessing the use of prophylactic clotting factor concentrates, to there being evidence that the use of these concentrates is effective in decreasing the frequency of joint bleeds and in partially preventing or slowing down the development of arthropathy.</P>
<P>The number of participants included in the review has increased from 37 to 142, with two new studies added.</P>
<P>Alfonso Iorio (previously a co-author) is now lead author on this review and Kent Stobart (previously lead-author) is now a co-author. John Wu has stepped down from the review and Emanuela Marchesini, Maura Marcucci and Anthony Chan are new co-authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-07-09 15:56:32 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-09 15:48:09 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Please note:</P>
<P>We are aware that the update of this review is overdue. The original review team has stepped down and a new review team is in place and working on the update. The updated version of this review will be published in 2010.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-22 11:02:37 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-01-07 09:19:20 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="1" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>The text of the Reviewers' Conclusions in the abstract has been altered to make clear that there is a lack of evidence from randomised controlled trials for the use of prophylaxis.<BR/>
<BR/>No new references were found in the latest search for this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-07-10 16:35:55 +0100" MODIFIED_BY="Alfonso Iorio">
<INTERNAL_SOURCES MODIFIED="2011-07-10 16:35:30 +0100" MODIFIED_BY="Alfonso Iorio">
<SOURCE MODIFIED="2011-07-10 16:35:30 +0100" MODIFIED_BY="Alfonso Iorio">
<NAME>Alberta Research Centre for Child Health Evidence</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>This support was received for the firs edition of this systematic review</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-07-10 16:35:55 +0100" MODIFIED_BY="Alfonso Iorio">
<SOURCE MODIFIED="2011-07-10 16:35:55 +0100" MODIFIED_BY="Alfonso Iorio">
<NAME>Association of Hemophilia Clinic Directors of Canada</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>This support was received for the firs edition of this systematic review</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-07-20 13:59:15 +0100" MODIFIED_BY="Tracey Remmington">
<SUMMARY MODIFIED="2011-07-19 13:57:22 +0100" MODIFIED_BY="Tracey Remmington">
<TITLE MODIFIED="2011-07-19 13:54:22 +0100" MODIFIED_BY="Tracey Remmington">Regular clotting factor replacement therapy to prevent joint disease in people with severe hemophilia A or B</TITLE>
<SUMMARY_BODY MODIFIED="2011-07-19 13:57:22 +0100" MODIFIED_BY="Tracey Remmington">
<P>Hemophilia A and B are X-linked inherited bleeding disorders, in which the major clinical problem is repeated bleeding into joints. As this disorder progresses, joints become deformed and movement limited. Current therapy for treating and preventing bleeding includes plasma-derived or recombinant clotting factor concentrates. This review includes six randomised controlled trials. Two compare the regular use of clotting factor concentrates to prevent joint bleeds with their use 'on demand'. Four compare different regimens of regular use in children and adults with hemophilia. It was clearly evident that preventative therapy, as intravenous infusion of factor concentrate repeated more times a week and started early in childhood was able to reduce joint deterioration as compared to treatment administered after bleeding occurred. This favourable effect is due to a consistent reduction in total bleeds and hemarthrosis (bleeding into joints) and leads to a significant improvement in quality of life. Preventative therapy is linked to an increased factor usage and cost of treatment. We found weaker evidence (due to lack of data) to show preventative therapy reduced joint deterioration when treatment is started after joint damage has been established. Further studies are needed to establish the best preventative regimen, i.e. for example starting time, dosage frequency, minimally effective dose.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-07-19 14:11:23 +0100" MODIFIED_BY="Tracey Remmington">
<ABS_BACKGROUND MODIFIED="2011-07-19 13:45:52 +0100" MODIFIED_BY="Tracey Remmington">
<P>The hallmark of severe hemophilia is recurrent bleeding into joints and soft tissues with progressive joint damage, notwithstanding on-demand treatment. Prophylaxis has long been used but not universally adopted because of medical, psychosocial, and cost controversies.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-05-19 14:21:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>To determine the effectiveness of clotting factor concentrate prophylaxis in the management of people with hemophilia A or B.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-05-19 14:21:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register. In addition, we searched major electronic databases (MEDLINE, EMBASE, CENTRAL), handsearched relevant journals and abstract books and reference lists of relevant articles.</P>
<P>Last search of Group's Coagulopathies Trials Register: 07 April 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-05-26 12:32:24 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomised controlled trials and quasi-randomised controlled trials evaluating people with severe hemophilia A or hemophilia B receiving prophylactic clotting factor concentrates.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-05-26 11:33:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>Two authors independently reviewed studies for eligibility, assessed risk of bias and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-07-19 14:11:23 +0100" MODIFIED_BY="Tracey Remmington">
<P>Six studies (including 142 participants) were eligible for inclusion. Two compared three-times-a-week prophylactic administration with on-demand treatment in children with hemophilia. Pooled results from these two studies showed a rate ratio of 0.30 (95% confidence interval; 0.12 to 0.76) for all bleedings and 0.22 (95% confidence interval 0.08 to 0.63) for joint bleedings favouring prophylaxis. Results on the number of patients with preserved joints after three to seven years of follow-up were not pooled due to significant heterogeneity. Three of the remaining four studies evaluated hemophilia A; one showed a statistically significant decrease in frequency of joint bleeds with prophylaxis compared to placebo, with a rate difference of -10.73 (95% confidence interval -16.55 to -4.91) bleeds per year. Two studies compared two prophylaxis regimens, failing to demonstrate an advantage of one regimen over the other in terms of bleeding frequency. The fourth study evaluated hemophilia B and showed fewer joint bleeds with weekly (15 IU/kg) versus bi-weekly (7.5 IU/kg) prophylaxis, rate difference -3.30 (95% confidence interval -5.50 to -1.10) bleeds per year. Non-significant increases in both inhibitor and infectious complications were observed in patients on prophylaxis, which occurred more often when using long-term venous access.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-07-19 13:53:32 +0100" MODIFIED_BY="Tracey Remmington">
<P>There is strong evidence from randomised controlled trials and observational trials that prophylaxis preserves joint function in children with hemophilia as compared to on-demand treatment. There is insufficient evidence from randomised controlled trials to confirm the observational evidence that prophylaxis decreases bleeding and related complications in patients with existing joint damage. Well-designed randomised controlled trials and prospective observational controlled studies are needed to establish the best prophylactic regimen and to assess the effectiveness of prophylactic clotting factor concentrates in adult patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-07-20 13:59:15 +0100" MODIFIED_BY="Tracey Remmington">
<BACKGROUND MODIFIED="2011-07-20 10:37:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>Hemophilia is an X-linked bleeding disorder due to a coagulation factor deficiency (factor VIII for Hemophilia A and factor IX for Hemophilia B) and is classified according to clotting factor level: severe (with a baseline coagulation factor level of less than 1% of normal); moderate (with clotting factor levels of 1% to 5%); and mild (with a clotting factor greater than 5%).</P>
<P>People with moderate and mild haemophilia bleed rarely, and often only after trauma or in association with invasive procedures.</P>
<P>The frequency and severity of bleeding is greatest in people with severe hemophilia A or B, in which recurrent and often spontaneous bleeding into joints and soft tissues (since early childhood) is the hallmark of severity. The consequence of recurrent joint bleeding is the development of different degrees of haemophilic arthropathy.</P>
<P>The availability of clotting factor concentrates has radically changed the treatment of people with hemophilia, with a significant improvement of morbidity, mortality and quality of life (QoL) (<LINK REF="REF-Lusher-1997" TYPE="REFERENCE">Lusher 1997</LINK>). Since the introduction of clotting factor concentrates, the early on-demand treatment for acute bleeding episodes is now common practice. This has resulted in a decrease in the number of joint deformities with respect to untreated or minimally-treated patients (<LINK REF="REF-Ahlberg-1965" TYPE="REFERENCE">Ahlberg 1965</LINK>; <LINK REF="REF-Hilgartner-1974" TYPE="REFERENCE">Hilgartner 1974</LINK>).</P>
<P>However, observation of the natural history of haemophilic arthropathy in people on long-term on-demand treatment shows that this regimen is clearly sub-optimal. A milestone study in 1994 reported the results of a longitudinal observation of 477 males under 25 years of age with severe hemophilia A without inhibitors who were followed up for six years (<LINK REF="STD-Aledort-1994" TYPE="STUDY">Aledort 1994</LINK>). Patients treated on demand showed a progressive deterioration of their joint function in some or all of the joints examined. Repeated bleeding in the joints has been indicated as the mechanism which, through abnormal proliferation of the synovial tissue, leads to joint disruption. At the time of this report's publication, the preventive use of clotting factor concentrates given at regular intervals had already been adopted for several decades in Sweden (<LINK REF="STD-Nilsson-1976" TYPE="STUDY">Nilsson 1976</LINK>). Then in 1994, the Medical and Scientific Advisory Council (<LINK REF="REF-MASAC" TYPE="REFERENCE">MASAC</LINK>), of the United States of America's National Hemophilia Foundation reviewed the Swedish experience with prophylaxis and issued guidelines stating that prophylaxis should be considered the optimal therapy for children with severe hemophilia A and B (<LINK REF="REF-NHF-1994" TYPE="REFERENCE">NHF 1994</LINK>).</P>
<P>In the meanwhile, the focus of managing an individual with hemophilia has changed from treating an acute bleeding episode to the comprehensive care of the individual, including the administration of clotting factor concentrate outside the hospital or treatment centre, as subsequently theorized and better defined (<LINK REF="REF-Teitel-2004" TYPE="REFERENCE">Teitel 2004</LINK>).</P>
<P>In fact, the efficacy of prophylaxis is expected to be higher if started early, i.e. before the establishment of any degree of joint deterioration, and continued as much as possible, as only home care treatment allows.</P>
<P>In this perspective, currently agreed definitions of prophylaxis are those proposed by the European Paediatric Network for Haemophilia Management (<LINK REF="REF-Berntorp-2003" TYPE="REFERENCE">Berntorp 2003</LINK>; <LINK REF="REF-Ljiung-2000" TYPE="REFERENCE">Ljiung 2000</LINK>). In particular, prophylaxis was defined as:</P>
<UL>
<LI>primary A (determined by age) if regular continuous treatment is started after the first joint bleed and before the age of two years;</LI>
<LI>primary B (determined by first bleed) if regular continuous treatment is started before the age of two years without previous joint bleeds;</LI>
<LI>secondary A if regular continuous (long-term) treatment is started after two or more joint bleeds or at an age of over two years;</LI>
<LI>secondary B if intermittent regular (short-term) treatment is applied, based on frequent bleed events.</LI>
</UL>
<P>Primary prophylaxis (A or B) and secondary A regimens require at least three doses per week for 42 weeks per year.</P>
<P>Despite the above recommendations, prophylaxis has not been universally adopted because of medical, psychosocial, and cost controversies (<LINK REF="REF-Blanchette-2004" TYPE="REFERENCE">Blanchette 2004</LINK>). In fact, the use of clotting factor concentrates is the single largest predictor of overall cost in the care of people with hemophilia (<LINK REF="REF-Miners-2004" TYPE="REFERENCE">Miners 2004</LINK>; <LINK REF="REF-Miners-2009" TYPE="REFERENCE">Miners 2009</LINK>), and it prevents its extensive application worldwide. Furthermore, there is no general agreement on the optimal prophylaxis regimen, and some schemes differ from that proposed by the European Paediatric Network which has been recently proven to be feasible (<LINK REF="STD-Feldman-2006" TYPE="STUDY">Feldman 2006</LINK>; <LINK REF="REF-Collins-2009" TYPE="REFERENCE">Collins 2009</LINK>). In addition, evidence is accumulating about the efficacy of secondary prophylaxis started in adulthood to slow the progression of hemophilic arthropathy in already damaged joints or to relieve symptoms, or both, and improve QoL (<LINK REF="REF-Fisher-2003" TYPE="REFERENCE">Fisher 2003</LINK>; <LINK REF="REF-Hay-2007" TYPE="REFERENCE">Hay 2007</LINK>).</P>
<P>In order to help clarify the open issues and provide optimal treatment recommendations for as many people with hemophilia as possible, we aim to systematically appraise the available evidence for the effectiveness of prophylactic administration of factor concentrates</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-07-20 10:38:03 +0100" MODIFIED_BY="Tracey Remmington">
<P>The objective of this review is to evaluate whether the preventive use of clotting factor concentrates in people with hemophilia A or B improves short- and long-term outcomes as measured by one or more of the following:</P>
<SUBSECTION>
<HEADING LEVEL="2">Short-term</HEADING>
<OL>
<LI>number of bleeding episodes per year or bleeding frequency</LI>
<LI>clotting factor concentrate plasma levels</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Long-term</HEADING>
<OL>
<LI>clinical joint function</LI>
<LI>orthopedic joint score</LI>
<LI>radiologic joint score</LI>
<LI>QoL measurements</LI>
</OL>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2011-07-20 11:02:30 +0100" MODIFIED_BY="Tracey Remmington">
<SELECTION_CRITERIA MODIFIED="2011-07-20 10:38:13 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_STUDIES MODIFIED="2010-04-26 17:49:29 +0100" MODIFIED_BY="Emanuela Marchesini">
<P>Randomised or quasi-randomised clinical trials. All identified trials, unpublished or published as an article, an abstract or a letter, without any language limitations, were eligible.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children and adults with congenital hemophilia A or B, including all ages and all degrees of severity. People with factor VIII or IX inhibitors were excluded. <BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-05-26 12:47:51 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trials included were those where intravenous clotting factor concentrates were administered as prophylactic treatment in any formulation (fresh frozen plasma, cryoprecipitate, lyophilised plasma derived clotting factor concentrate, or recombinant clotting factor concentrate), any concentration, any frequency and any dose were compared with no treatment, or on-demand treatment, or with one or more different prophylaxis regimens. The duration of treatment was greater than a single treatment. At least one treatment had to be a clotting factor concentrate.</P>
<P>Therefore the comparison groups are as follows:</P>
<OL>
<LI>prophylaxis versus placebo;</LI>
<LI>prophylaxis versus on-demand treatment;</LI>
<LI>prophylaxis versus alternative prophylaxis.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-07-20 10:38:13 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-31 14:05:02 +0000" MODIFIED_BY="Tracey Remmington">
<OL>
<LI>Number of bleeding episodes or bleeding frequency</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-07-20 10:38:13 +0100" MODIFIED_BY="Tracey Remmington">
<OL>
<LI>Pain scores</LI>
<LI>Radiologic joint score or radiologic measurements or descriptions of joint damage</LI>
<LI>Orthopedic joint score or clinical joint function</LI>
<LI>QoL</LI>
<LI>Clotting factor concentrate plasma levels</LI>
<LI>Time loss to school or employment</LI>
<LI>Integration into society</LI>
<LI>Scales recording feeling of well-being and global functioning</LI>
<LI>Cost effectiveness, cost benefit, cost utilization, cost minimization</LI>
<LI>Any reported adverse effects or toxicity of clotting factor concentrates will be recorded (e.g. inhibitors, reactions, transmission of infection)</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-07-10 14:01:29 +0100" MODIFIED_BY="Alfonso Iorio">
<ELECTRONIC_SEARCHES MODIFIED="2011-07-10 14:01:29 +0100" MODIFIED_BY="Alfonso Iorio">
<P>Relevant trials were identified from the Group's Coagulopathies Trials Register using the term: prophylaxis and hemophilia* or haemophilia*.</P>
<P>The Coagulopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (Clinical Trials) (updated each new issue of <I>The Cochrane Library</I>) and quarterly searches of MEDLINE and the prospective handsearching of one journal - <I>Haemophilia</I>. Unpublished work is identified by searching the abstract books of major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; and the Congress of the World Federation of Hemophilia. For full details of all searching activities for the register, please see the relevant section of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/cf/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Group's Coagulopathies Trials Register: 07 April 2011.</P>
<P>We performed additional searches on MEDLINE (from January 1966 to 14 February 2011), and EMBASE (from 1988 to 14 Feburary 2011) (both on the OVID platform) and CENTRAL (Issue 4, 2010). For the full search strategies, please refer to the appendices (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-05-19 14:19:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>The bibliographic references of all retrieved studies and reviews were assessed for additional reports of clinical trials. For the 2011 update, handsearching of the proceedings of the International Society for Thrombosis and Haemostasis bi-annual meeting and proceedings of the European Association for Haemophilia and Allied Disorders were performed for the years 2004 to 2010.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-07-20 11:02:30 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_SELECTION MODIFIED="2011-05-26 12:59:39 +0100" MODIFIED_BY="Tracey Remmington">
<P>Two authors independently examined the titles and abstracts of trials generated from the database searches to identify potentially relevant studies. They retrieved complete manuscripts for all potentially relevant studies. With the full text manuscripts, the authors independently assessed the studies using a standardised form. They resolved differences, regarding which studies to include, by consensus reached after discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-05-26 13:11:36 +0100" MODIFIED_BY="Tracey Remmington">
<P>Using a structured data form the authors extracted the following information: characteristics of the study; study participants' demographics; the study intervention and co-interventions (including doses of clotting factor concentrate); study outcomes (including primary and secondary outcomes). Two authors extracted data independently and compared the results. They resolved differences by consensus and referral to the original paper.</P>
<P>Authors considered outcome data if recorded as either individual events or as events grouped by time periods.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-07-20 09:51:46 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors used the standard built-in tool in RevMan 5.1 to measure the risk of bias and to produce summary figures (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
<P>The authors assessed the risk of bias using the 'Risk of bias' assessment tool as documented in section 8.5 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The following domains were assessed as having either a low, high or unclear risk of bias:</P>
<UL>
<LI>sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding (of participants, personnel and outcome assessors);</LI>
<LI>incomplete outcome data;</LI>
<LI>selective outcome reporting;</LI>
<LI>other sources of bias.</LI>
</UL>
<P>Results of the risk of bias assessment are displayed in the risk of bias tables in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-07-20 10:23:25 +0100" MODIFIED_BY="Tracey Remmington">
<P>We expected rates of events to be the measures reported for the primary outcome. We expected rate of events or mean and standard deviations (SD) to be the measures reported for most of the secondary outcomes. Consequently, and taking also into account the high number of events expected for the primary outcome, the authors chose the rate difference as the measure of treatment effect for the primary outcome and risk difference or the mean difference (MD) for the secondary outcomes. The authors accounted for any deviation from this plan in the text.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-07-20 09:49:32 +0100" MODIFIED_BY="Tracey Remmington">
<P>Hemophilia lends itself to cross-over study design, as it is a chronic incurable genotypically-stable disease, and treatment with clotting factor concentrate has a rapid onset and short duration as the factor VIII and IX physiological half-lives are 12 and 24 hours respectively. Thus, we expected at least some of the studies to be cross-over in design. As a pre-planned analysis we stated that we would use the generic inverse variance (GIV) method when individual patient data were available or after obtaining the relevant data. If such data were available, we would have analysed any parallel group studies the same way to allow pooling of data. Otherwise, we used the standard RevMan method for parallel group trials (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-07-20 11:00:22 +0100" MODIFIED_BY="Tracey Remmington">
<P>We contacted two authors to obtain additional data, but to date, none have been received (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-07-10 14:59:47 +0100" MODIFIED_BY="Alfonso Iorio">
<P>If we had included a sufficient number of studies in any meta-analysis, then we would have assessed clinical heterogeneity by visual and statistical analysis. For future updates, if we include a sufficient number of studies, we will use the I<SUP>2</SUP> method to assess for heterogeneity in meta-analysis. If I<SUP>2</SUP> is equal to or greater than 50% we will consider this indicative of heterogeneity. We have reported both I<SUP>2</SUP> and Cochran Q chi -squared values.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-07-20 09:50:53 +0100" MODIFIED_BY="Tracey Remmington">
<P>We planned to look for publication bias, checking open trial registries (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>) and using visual inspection of the funnel plot graph (if there were 10 or more included studies). Given the rarity of the disease and its chronic course, we believe publication bias is unlikely to occur since any similar trials would have been openly planned and run in the small hemophilia community. We investigated outcome reporting bias by looking for differences between trial reports and the original protocols or challenging any relevant unreported outcome data.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-05-26 13:29:01 +0100" MODIFIED_BY="Tracey Remmington">
<P>Due to the low number of available studies, we have conducted the meta-analyses of the primary data using a random-effects model.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-07-20 11:02:30 +0100" MODIFIED_BY="Tracey Remmington">
<P>We undertook a <I>post hoc </I>sensitivity analysis for adverse events (central venous catheter (CVC) patients) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>)</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-07-20 13:58:04 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_DESCRIPTION MODIFIED="2011-07-20 10:10:03 +0100" MODIFIED_BY="Tracey Remmington">
<SEARCH_RESULTS MODIFIED="2011-07-20 09:56:44 +0100" MODIFIED_BY="Tracey Remmington">
<P>In the study search for the first edition of this systematic review, using the above search strategies, 890 unique references were identified. The authors assessed the titles and abstracts, from which 119 unique new articles were retrieved, 29 studies were considered for inclusion and 4 were finally included. One additional study was identified by contacting the primary author of an identified congress abstract. The original selection and extraction was performed by KS and AI.</P>
<P>Study selection and data extraction for the 2011 update were performed in duplicate by EM and MM. A total of 569 new references were retrieved, from which 82 unique references were identified by title and abstract scanning and 9 unique articles were identified as being potentially relevant. Three new references (to two studies) were finally included. Data about the 'Joint Outcome Study (JOS)' were provided by two of these references (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>), while data about the ESPRIT study were retrieved in one reference (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). Additional details about these two studies were requested from the authors (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). For the JOS study we requested additional details about inhibitors (distributions into the two treatment arms and inhibitor levels); the data were partially provided by dr Manco-Johnson.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-07-20 10:05:41 +0100" MODIFIED_BY="Tracey Remmington">
<P>Six studies, with a total of 142 participants, were identified as being relevant and included in the data analysis (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). There was no disagreement between the two authors with respect to study relevance. The six studies were heterogeneous as each study used a different intervention. Given the available data, a meta-analyses could be performed for two studies (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>).</P>
<P>One study was performed in the USA (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>) and five studies were conducted in Europe. Two studies were conducted in Italy (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>), one in Sweden (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>) and two in England (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>). The four participants in the second English study had participated in the earlier one. There were approximately six months between the completion of the first study and the commencement of the second. All studies were published in English.</P>
<P>Two studies were randomised controlled open studies (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). Four were cross-over in design (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>), and all six used bleed frequency as the primary outcome measure. The interventions were not similar between the studies, leading to heterogeneous results and an inability to perform an overall meta-analysis. The two more recent studies allowed us to pool data for some of the outcomes (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Types of Participants</HEADING>
<P>The JOS study included patients on primary prophylaxis (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>); the ESPRIT study included patients in primary and secondary prophylaxis (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>); the remaining four trials reported data about secondary prophylaxis (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>;.<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>).</P>
<P>In one study the participants were people with severe hemophilia B (factor IX less than 1%) (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). In three studies the participants were people with severe hemophilia A (factor VIII less than 1%) (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). One study included people with clinically severe hemophilia, where one participant had a pharmacological moderate level of factor VIII (1.5%), but behaved clinically as a person with severe hemophilia A (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). The JOS study included people with severe and moderate-severe hemophilia A with factor VIII level below than 2% (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>).The age range of participants was from 1 year to 45 years. All participants were male, and none had inhibitors. The studies varied in sample size with 9, 4, 14, 40, 65 and 10 participants respectively (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of Interventions</HEADING>
<P>Four studies were cross-over in design (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). The order of the intervention was randomised, and all participants received both the control and active treatment. Different interventions were used in the four studies. The treatment arm was either a larger amount (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK> ) or a more frequent dosing schedule (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>) of clotting factor concentrate than the control arm, or a modified prophylaxis dose of clotting factor concentrate based on individual pharmacokinetic data (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). The control arm was either a non-physiologic effective dose of clotting factor concentrate (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>), a physiologic effective clotting factor concentrate dose (<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>), or a standard prophylaxis schedule of clotting factor concentrate (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). In the Carlsson study, upon enrolment in the clinical trial, each patient received a single standard dose of clotting factor concentrate (factor VIII 25 to 40 IU/kg), and a pharmacokinetic evaluation was calculated by standard "model-independent" procedures; the individual's pharmacokinetic data were used to fit computer-simulated multiple-dose activity curves of factor VIII for each case, to clinically achieve a factor VIII trough level above 1% (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>).</P>
<P>One study compared a regimen of clotting factor concentrate to increase the factor VIII dose to 25% of the normal compared to 1% of the normal (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>). A second study compared bi-weekly dosing of clotting factor concentrate to raise factor VIII to 30% of normal, versus 15% of normal (<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>). The study by Morfini compared the same total dose of factor IX clotting factor concentrate per week, administered either weekly (15 IU/kg) or bi-weekly (7.5 IU/kg) (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). The study by Carlsson compared standard dose prophylaxis (25 to 40 IU/kg/dose) given three times per week with the dose and interval based on individual pharmacokinetic data (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). In all four studies, the clotting factor concentrate dosing interval allowed a physiological washout period of treatment effect before the cross-over intervention was undertaken.</P>
<P>The two new studies at the 2011 update were open randomised controlled trials (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>).These studies compared a prophylaxis treatment group versus an on-demand treatment group. One study compared a prophylaxis group with a factor VIII infusion of 25 IU/kg of body weight every other day versus on-demand treatment with 40 IU/kg of body weight at the time of joint haemorrhage followed by 20 IU at 24 hours and 72 hours after the first dose (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). When hemarthroses occurred in the prophylaxis group, patients were treated with 40 IU/kg at the time of joint haemorrhage. The second trial compared prophylactic treatment with 25 IU/kg of body weight three-times weekly versus on-demand treatment with 25 IU/kg of body weight until complete healing (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of Outcomes</HEADING>
<P>The primary outcome of interest, bleeding events or bleed frequency, was reported in all six studies. All outcomes were standardized to event rates per year.</P>
<P>Range of motion of affected joints was collected in one study, but the data were collected at the completion of the study, after the participants had experienced both interventions in a cross-over fashion (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). Data about long-term joint deterioration and adverse events (inhibitors rate, and infection) were reported in two studies (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>).</P>
<P>A secondary outcome reported in one study was 'morbidity', and it was defined as "time spent in the college sick bay or at hospital, where more than three hours under medical care was noted as one day" (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>). A further secondary outcome that was reported in three studies was the quantity of clotting factor concentrate administered (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). Quality of life data were reported in one study (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-07-20 10:10:03 +0100" MODIFIED_BY="Tracey Remmington">
<P>Thirty-one studies were excluded because they were not RCTs. We classified these as controlled observations and included them in an additional table because of their potential use in estimating the baseline risk and variability of treatment effect size in different populations (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Twenty-five studies were excluded after the first search, an additional reference to one of these studies was identified during a later search (<LINK REF="STD-Feldman-2006" TYPE="STUDY">Feldman 2006</LINK>). Six other studies were excluded from the analysis at the 2011 update and details are presented in the additional tables (<LINK REF="STD-Collins-2010" TYPE="STUDY">Collins 2010</LINK>; <LINK REF="STD-Fischer-2005" TYPE="STUDY">Fischer 2005</LINK>; <LINK REF="STD-Nemes-2007" TYPE="STUDY">Nemes 2007</LINK>; <LINK REF="STD-Schobess-2008" TYPE="STUDY">Schobess 2008</LINK>; <LINK REF="STD-Tagliaferri-2008" TYPE="STUDY">Tagliaferri 2008</LINK>; <LINK REF="STD-Wu-2011" TYPE="STUDY">Wu 2011</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-07-20 10:20:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>An overall graphical representation of the risk of bias assessment is provided in the figures (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). It was noted in particular, in relation to blinding, the risk of bias was found to be high in two studies (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). In relation to 'other potential sources of bias', one trial was assessed as having a high risk of bias due to a significant number of patients crossing over the allocated treatment arms (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>).</P>
<ALLOCATION MODIFIED="2011-07-20 10:13:44 +0100" MODIFIED_BY="Tracey Remmington">
<P>All six studies were described as being randomised, but none reported details about sequence generation. Four studies were judged as having suitable concealment (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). In the remaining two studies there was no allocation concealment (<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977;</LINK> <LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-07-20 10:14:47 +0100" MODIFIED_BY="Tracey Remmington">
<P>One study described an appropriate method of double blinding, where the physicians administering the study treatment were in a different institution from the physicians evaluating and treating bleeding episodes (<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>). Two studies stated that the patients were unaware of the treatment administered by the physician (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>). The ESPRIT study had a blinded assessment of orthopedic and radiographic scores (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). The JOS study had blinded assessment of orthopedic and radiographic scores and of laboratory assessments (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). The remaining trials were unblinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-07-20 10:16:43 +0100" MODIFIED_BY="Tracey Remmington">
<P>All six studies discussed withdrawals. Two studies had no withdrawals (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>). One study had two withdrawals, these were voluntary discontinuations by two participants who bled soon after a low dose administration (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>). The fourth trial had seven withdrawals (four withdrew their consent, three had an unpredictable pharmacokinetic modified dosage schedule) (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). The ESPRIT study was analysed by intention-to-treat, and recorded 8 withdrawals (4 in each arm) (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). The JOS study reported 5 (out of 32) withdrawals in the prophylaxis group and 11 (out of 33) (3 for life-threatening haemorrhages) in the on-demand group (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). This study was analysed by intention-to-treat.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-07-20 10:18:12 +0100" MODIFIED_BY="Tracey Remmington">
<P>Selective reporting was assessed only for trials with registered protocols. The only protocol found was for the JOS trial, registered at the end of enrolment (September 2005) on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> (NCT00207597) (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). All the outcomes reported in the protocol were analysed in the published paper. The main outcome was identical in the protocol and the published paper. For the remaining studies we assessed correspondence between methods and results sections. It was difficult to judge the occurrence of non reporting of clinically relevant for the older trials included in the review.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-07-20 10:20:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>It was reported in three studies that they were sponsored by pharmaceutical companies (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). One study did not record sponsorship (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>). Three studies received financial support from external sources (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). A significant degree of cross-over between the two treatment arms was reported for ESPRIT trial (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). The four studies designed as cross-over did not have a wash out period and did not take any other method to avoid or account for carry-over effect.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-07-20 13:58:04 +0100" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="3">Standard prophylaxis regimen compared to a placebo regimen</HEADING>
<P>One study was included in the comparison (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>). The characteristics of the included study were:</P>
<UL>
<LI>
<B>Type of prophylaxis: </B>secondary prophylaxis</LI>
<LI>
<B>Age range: </B>13 years to 17 years old</LI>
<LI>
<B>Follow-up duration: </B>at least two school terms</LI>
<LI>
<B>Number of enrolled patients: </B>9</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Bleeding frequency</HEADING>
<P>The clinical trial found a statistically significant advantage for the higher dose of factor VIII as compared to a non-physiologic dose with a rate difference for bleeding frequency of -10.73 (95% CI -16.55 to -4.91) bleeds per year (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Pain Scores</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Radiologic joint score</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Orthopedic joint score</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4<I>.</I> QoL</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5<I>.</I> Clotting factor concentrate levels</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6<I>.</I> Time loss to school or employment</HEADING>
<P>The study assessed morbidity, defined as "time spent in the college sick bay or at the hospital" (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The mean rate difference was statistically significant (P &lt; 0.05), favouring treatment of children on the high-dose regimen (factor VIII 0.25 IU/kg), who spent less time confined to bed, rate difference 0.28 (95% CI 0.20 to 0.40). In this trial individual participant data were not provided, and therefore a logarithmic rate difference was calculated (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7<I>.</I> Integration into society</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Well-being and global functioning</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Cost effectiveness, cost benefit, cost utilization, cost minimization</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10<I>.</I> Adverse events</HEADING>
<P>The study summarized adverse events or complications at the end of the study, after participants had received both the treatment and control interventions. However, no participant developed a factor VIII inhibitor or became hepatitis B surface antigen positive during the clinical trial (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Standard prophylaxis regimen compared to on-demand treatment</HEADING>
<P>Two studies were included in the comparison (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>; <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). The characteristics of the include studies were:</P>
<P>
<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>
</P>
<UL>
<LI>
<B>Type of prophylaxis: </B>secondary and primary prophylaxis .</LI>
<LI>
<B>Age range: </B>less than seven years old</LI>
<LI>
<B>Follow-up duration: </B>median 82.5 months (range: 2 months to 163 months)</LI>
<LI>
<B>Number of enrolled patients: 40</B>
</LI>
</UL>
<P>
<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>
</P>
<UL>
<LI>
<B>Type of prophylaxis: </B>primary prophylaxis</LI>
<LI>
<B>Age range: </B>less than 30 months</LI>
<LI>
<B>Follow-up duration: </B>mean 49 months (range: 48 to 58 months)</LI>
<LI>
<B>Number of enrolled patients: 65</B>
</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Bleeding frequency</HEADING>
<P>The comparison showed a significant statistical reduction of total bleeding in patients treated on prophylaxis versus those treated on demand. The rate difference was calculated for the JOS study only (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>), since the SD for the main effect was not reported for the ESPRIT study (because of skewed data distribution) and not provided by the authors upon request (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). The rate difference for the JOS study was -14.42 (SD 7.91) for bleed frequency and -4.16 (SD 2.71) for joint bleeds. To provide a pooled estimate of the effect on bleeding rate, the rate ratio was used, rate ratio 0.30 (95% CI 0.12 to 0.76), I<SUP>2 </SUP>99% (Chi<SUP>2</SUP> 196.78, P &lt; 0.00001) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). A similar significant reduction was found when pooling results for joint bleeding, rate ratio 0.22 (95% CI 0.08 to 0.63), I<SUP>2 </SUP>98% (Chi<SUP>2</SUP> 63.31, P &lt; 0.00001) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). The pooled estimates should be considered with caution due to the very high level of heterogeneity, very likely due to the different characteristics of the population in the two studies. The absolute bleeding rates in the control groups were for all bleedings 17.7 +/- 9.2 (events per patient per year, mean and SD) in the JOS study and 0.48 (events per patient per month, mean) in the ESPRIT study; for joint bleedings 4.9 +/- 3.6 (events per patient per year, mean and SD) in the JOS study and 0.24 (events per patient per month) in the ESPRIT study for joint bleeds.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Pain Scores</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Radiologic joint score</HEADING>
<P>We did not pool the data for this outcome due to two additional causes of variability in the two studies (duration of follow-up and the intensity of treatment in the control group (enhanced on-demand prophylaxis in the JOS study)). Only patients on primary prophylaxis in the ESPRIT study showed a statistically significant protection from joint damage with prophylaxis when this was compared to standard on-demand treatment (risk difference 0.70 (95% CI 0.39 to 1.01) while the difference in the JOS study was borderline significant, risk difference 0.15 (95% CI -0.01 to 0.31) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). The effectiveness of secondary prophylaxis was tested in the ESPRIT study only, resulting in a non-significant difference, risk difference for reduction in the progression of radiologic evidence of joint damage 0.32 (95% CI -0.07 to 0.70) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Orthopedic joint score</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4<I>.</I> QoL</HEADING>
<P>Only the ESPRIT trial reported data on QoL (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). The Haemo-QoL questionnaire showed that overall QoL was of 22.2 (SD 8.2), in a scale from 0 to 100, where 100 indicates completely deteriorated QoL. When assessing the impact of treatment, a significant difference was found in children receiving on-demand treatment versus those receiving prophylaxis in the sub-scale exploring the dimension "family", which was more impaired in the on-demand treatment group, MD 32.73 (95% CI 22.30 to 43.16) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5<I>.</I> Clotting factor concentrate usage</HEADING>
<P>The studies showed a significant increased consumption of factor VIII in the patients treated with prophylaxis as compared to those treated on demand. Monthly factor usage per patient on the ESPRIT trial was 8852 IU and 3981 IU in the prophylaxis group and in the on-demand group, respectively (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>) and in the JOS study they were 5880 IU and 1887 IU per patient per month in the prophylaxis group and in the on-demand group respectively, MD 5270 IU/month per patient (95% CI 4230 to 6320), I<SUP>2</SUP> 0% (Chi<SUP>2</SUP> 0.24, P = 0.62) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6<I>.</I> Time loss to school or employment.</HEADING>
<P>The outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7<I>.</I> Integration into society</HEADING>
<P>The outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Well-being and global functioning</HEADING>
<P>The outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Cost effectiveness, cost benefit, cost utilization, cost minimization</HEADING>
<P>In the ESPRIT study a cost analysis was performed (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). Cost evaluation was based on the annual FVIII consumption. A societal perspective was adopted (third party payer, i.e. the Italian National Health Service), and all the health care resources absorbed by the care of patients were specifically considered. With an average price per IU of recombinant factor VIII concentrates of EUR 0.75, the cost for one year of prophylaxis was EUR 79,668 compared to EUR 35,829 for one year on on-demand therapy. The incremental cost-efficacy ratio per bleeding events avoided in patients on prophylaxis was EUR 7537. The incremental cost-efficacy ratio for maintaining all joints unaffected over the whole treatment period was EUR 201,601.12.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10<I>.</I> Adverse events</HEADING>
<P>Both studies reported the rate of infections per treatment group. When all the enrolled patients were considered, a non-significant difference against prophylaxis was observed, risk difference 0.14 (95% CI -0.14 to 0.42), I<SUP>2</SUP> 75% (Chi<SUP>2</SUP> 4.04, P = 0.04) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). Analysis of the inhibitor rate was complicated by suboptimal reporting of inhibitor incidence in both studies. In the Gringeri study, the incidence of inhibitors was reported without providing the distribution in high or low-responding/transient inhibitors (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>). In the JOS study, the assignment to treatment group of seven low-responding/transient inhibitors was not provided (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). Both authors were contacted to obtain additional data, but to date, none have been received. When compared using the data as reported in the publications, the inhibitor rate was not significantly higher in patients on prophylaxis, risk difference 0.06 (95% CI -0.03 to 0.15) I<SUP>2</SUP> 0% (Chi<SUP>2</SUP> 0.06, P = 0.81) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Adverse events in central venous catheter (CVC) patients (sensitivity analysis)</HEADING>
<P>Since both infections and inhibitor development are reported to be more common in patients with CVC, we also analysed adverse events in this subgroup of patients. Data allowing the comparison were available from the JOS study only (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>), since in the ESPRIT study only patients on prophylaxis had CVC placed (6 out of 10) (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>), and no infection or incidence of inhibitors were recorded in patients without a central vein access. A non-significant difference was observed, risk difference -0.03 (95% CI -0.26 to 0.19) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). In a further sensitivity analysis, we calculated the number of patients with CVC and events in the two studies (6/10 additional patients in the ESPRIT prophylaxis group), ending with 12/39 and 6/25 infections during prophylaxis or on-demand treatment in CVC patients, respectively, and recalculated an unadjusted risk difference of 0.07 (95% CI -0.15 to 0.29). Similarly for inhibitor rate we found a non-significant excess of inhibitors in CVC patients on prophylaxis versus those on demand (1 out of 29 versus 1 out of 25, respectively with a risk difference of -0.01 (95% CI -0.11 to 0.10)) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>), unadjusted risk difference 0.06 (95% CI -0.06 to 0.18).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Standard prophylaxis regimen compared to an alternative prophylaxis regimen</HEADING>
<P>Three studies were included in this comparison but could not be aggregated as one study compared bi-weekly dosing of clotting factor concentrate given at a dose to raise factor VIII to 30% of normal, versus a dose to get 15% of normal factor VIII concentrate post-infusion level (<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>), a second study was on people with hemophilia B (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>), and the third compared standard dose prophylaxis (25 to 40 IU/kg/dose) given three times per week with a regimen in which the dose and interval were based on individual pharmacokinetic data (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>) .<B>
<I> </I>
</B>
</P>
<P>The characteristics of the include studies were:</P>
<P>
<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>
</P>
<UL>
<LI>
<B>Type of prophylaxis: </B>secondary prophylaxis</LI>
<LI>
<B>Age range: </B>13 years to 17 years old</LI>
<LI>
<B>Follow-up duration: </B>at least two school term</LI>
<LI>
<B>Number of enrolled patients: </B>4</LI>
</UL>
<P>
<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>
</P>
<UL>
<LI>
<B>Kind of prophylaxis: </B>secondary prophylaxis</LI>
<LI>
<B>Age range: </B>8 years to 42 years old</LI>
<LI>
<B>Follow-up duration: </B>one year</LI>
<LI>
<B>Number of enrolled patients: </B>21 (14 included in the analysis)</LI>
</UL>
<P>
<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>
</P>
<UL>
<LI>
<B>Kind of prophylaxis: </B>secondary prophylaxis</LI>
<LI>
<B>Age range: </B>5 years to 45 years old</LI>
<LI>
<B>Follow-up duration: </B>one year</LI>
<LI>
<B>Number of enrolled patients: </B>10</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Bleeding frequency</HEADING>
<P>Two studies did not find a statistical significant effect in the bleeding frequency: rate difference of -5.04 (95% CI -17.02 to 6.94) bleeds per year when comparing two different dosages (<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>); and rate difference -0.14 (95%CI -1.34 to 1.05) bleeds per year when assessing a PK-based regimen (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). The Morfini study showed a significant difference in favour of the bi-weekly versus the once weekly dosing group, rate difference of -3.30 (95% CI -5.50 to -1.10) bleeds per year (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>Note: as the dosage and frequency of administration of the clotting factor concentrate was different in the three studies, it was not possible to combine the studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Pain Scores</HEADING>
<P>No studies reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2<I>.</I> Radiologic joint score</HEADING>
<P>The radiological assessments in people with factor IX deficiency were made at the completion of the study, not at the completion of the separate interventions. Therefore, it was not possible to attribute effectiveness of the treatment intervention in this cross-over design study (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Orthopedic joint score</HEADING>
<P>The clinical orthopedic evaluations in people with factor IX deficiency were collected at the completion of the study, not at the completion of the separate interventions. Therefore, it was not possible to attribute effectiveness of the treatment intervention in this cross-over design study (<LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4<I>.</I> Quality of life</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5<I>.</I> Clotting factor concentrate levels</HEADING>
<P>One study reported clotting factor concentrate usage (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). There was a significant difference in favour of the pharmacokinetic-optimised dosing group, mean difference of -3300 IU per month (95%CI -1420 to -5180) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6<I>.</I> Time loss to school or employment</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7<I>.</I> Integration into society</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Well-being and global functioning</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Cost effectiveness, cost benefit, cost utilization, cost minimization</HEADING>
<P>One study reported savings with a PK-based regimen as compared to a standard prophylaxis regimen (<LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>). Savings for 14 patients over 6 months were USD 418,000 or GBP 270 (as calculated in 1997).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10<I>.</I> Adverse events</HEADING>
<P>Two studies summarized adverse events or complications at the end of the study, after participants had received both the treatment and control interventions. The development of factor VIII inhibitors or positivity to hepatitis B surface antigen was collected at the completion of the study, but no participants developed an inhibitor or became newly hepatitis B surface antigen positive (<LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-07-20 13:59:07 +0100" MODIFIED_BY="Tracey Remmington">
<P>This systematic review included six studies with a total of 142 participants with a different degree of arthropathy at baseline and variable types of interventions, which allowed only partial aggregation of data for clotting factor concentrate usage for the prevention of bleeding in people with hemophilia. On the whole, these studies provided evidence that prophylactic administration of clotting factor concentrates is effective in significantly preventing or slowing down the progression of hemophilic arthropathy. As a caveat, performing primary prophylaxis (i.e. started before a significant number of bleeds has occurred) in small children often requires clinicians to implant a venous access device. The use of these devices is complicated by local infection in a significant number of cases. Similarly, patients on prophylaxis in these studies developed more inhibitors than those receiving on-demand therapy, although the difference was not statistically significant and potentially associated with venous access implants or infection rather than to the prophylactic regimen.</P>
<P>The clinical management of people with hemophilia has changed over the past three decades, i.e. since the oldest clinical studies included in this review were undertaken. Hemophilia care is now provided under a comprehensive health care model and with prophylactic or on-demand treatment for the majority of bleeds given at home, i.e. outside the treatment centre.</P>
<P>The dates of publication of the earlier studies and the events that have occurred in the intervening years is worthy of comment. Three of the included studies were performed as early as the 1970s. Subsequently, the unfortunate events of the blood-borne infectious disease epidemic precluded the design and implementation of well-designed clinical trials in the 1980s. Later on, the introduction of recombinant human clotting factor concentrates removed any residual risk of infection. However, the ability to undertake a RCT on the effectiveness of prophylaxis was overshadowed by more than 20 years experience of primary prophylaxis with clotting factor concentrate compared to historical controls (<LINK REF="STD-Nilsson-1992" TYPE="STUDY">Nilsson 1992</LINK>; <LINK REF="STD-Petrini-1991" TYPE="STUDY">Petrini 1991</LINK>; <LINK REF="STD-Brackmann-1992" TYPE="STUDY">Brackmann 1992</LINK>; <LINK REF="STD-Manco_x002d_Johnson-1994" TYPE="STUDY">Manco-Johnson 1994</LINK>; <LINK REF="REF-van-den-Berg-2002" TYPE="REFERENCE">van den Berg 2002</LINK>). Although not RCTs, the observational studies indicated clear benefits in the reduction of bleed frequency and joint deformity. It has therefore been very difficult for investigators to decide if there was true equipoise in the choice between prophylactic and on-demand treatment. Essentially, coupled with this established pattern of practice, there are 30 unique observational studies reporting data from 1960 people with hemophilia undergoing clotting factor concentrate prophylaxis in comparison with 1312 people with hemophilia treated on-demand. Detailed characteristics of these observational studies are listed in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). These non-RCT observational studies have been used by healthcare providers to justify the use of clotting factor concentrate in primary prophylaxis in several countries throughout the world. Finally, and notwithstanding all the evidence above, two independent groups in the USA (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>) and Italy (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>) found it ethically and scientifically sound to compare the widely-used thrice-a-week prophylaxis regimen with on-demand treatment. Both groups confirmed the superiority of administering prophylactic factor concentrates, by showing a reduction in the bleeding rate and progression of arthropathy. Both studies, however, demonstrated that hemophilia patients develop some degree of joint deterioration even when receiving prophylaxis. Furthermore, prophylaxis was found to be associated with a significant increase in the amount of resources used.</P>
<P>Why were the results of these two more recently performed studies positive and at variance with the four older studies? Bleeding episodes within and between people with hemophilia can vary considerably over a period of months. Furthermore, the pathologic process which leads to hemophilic arthropathy requires several years to produce clinically evident modifications in the affected joints. Only the two more recent of the six studies observed patients for 10 years (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>) and 4 years (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>), time-spans that can be considered long enough to establish a significant difference. Of the remaining four studies included in the analysis, two observed participants for one year, and two for two or four "English school" terms. The bleeding frequency period studied may have been too short to be clinically meaningful, and the cross-over design could have been suboptimal in assessing differences in the setting of chronic disease, where information about effectiveness and optimal duration of the washout period are largely unknown. Carryover effect from on-demand treatment to prophylaxis might have negatively biased the effect of prophylaxis, while carryover from prophylaxis to on-demand treatment may have positively inflated the effectiveness of on-demand treatment. Furthermore, it has been repeatedly shown that prophylaxis exerts its effect mostly in patients whose joints are still unaffected joints (i.e. after one or at maximum two clinically relevant bleeding episodes). Most of the participants in the older studies had already presented with some degree of hemophilic arthropathy (<LINK REF="STD-Aronstam-1976" TYPE="STUDY">Aronstam 1976</LINK>; <LINK REF="STD-Aronstam-1977" TYPE="STUDY">Aronstam 1977</LINK>; <LINK REF="STD-Carlsson-1997" TYPE="STUDY">Carlsson 1997</LINK>; <LINK REF="STD-Morfini-1976" TYPE="STUDY">Morfini 1976</LINK>), while the patients in the JOS study (<LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>) and some of those in the ESPRIT study (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>) qualified to be considered as receiving primary prophylaxis. Of note, even the two more recent studies, though focused on prophylaxis in children, presented a high degree of heterogeneity, most likely due to the difference in either the characteristics of the population included or the different treatment scheme used for the on-demand control group (<LINK REF="STD-Gringeri-2011" TYPE="STUDY">Gringeri 2011</LINK>, <LINK REF="STD-Manco_x002d_Johnson-2007" TYPE="STUDY">Manco-Johnson 2007</LINK>). Thus, the overall estimates of the meta-analyses should be considered with caution, and it may even have been inappropriate to pool the results of the two studies to give a point estimate. In addition to the estimate of the mean effect size, it is important that the clinical reader, when estimating the reduction in the bleeding frequency expected for a given patient, considers the appropriate value in the range of the confidence intervals, assuming that the baseline risk and the reduction are likely to be inversely correlated with the age and joint deterioration of the patient.The heterogeneity between the studies is most evident when considering the long-term effect of prophylaxis. In fact, only patients on primary prophylaxis in the ESPRIT study, where the control was standard on-demand treatment, showed a statistically significant protection of the joint function, while the difference in the JOS study, where enhanced prophylaxis was used as a comparator and the follow-up was shorter, was borderline significant (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3)</LINK>.</P>
<P>Prophylaxis has already been set as a standard in the western world, but there is still a lack of knowledge about several aspects of this treatment, as highlighted by the many outcomes that are considered relevant by hemophilia clinicians (and thus listed among the outcomes of interest for this review), but which have not been addressed or reported on by most of the studies. Furthermore, new randomised comparisons between different regimens to deliver prophylaxis are to be expected in the near future. In fact, during the course of the recent randomised studies and after their completion, several new issues about prophylaxis in hemophilia were raised, such as: optimal regimen (including both dose, frequency, individual tailoring by means of escalating-dose protocol or PK modelling); optimal starting point and regimen to preserve joint function and minimize inhibitor development (<LINK REF="REF-Kurnik-2010" TYPE="REFERENCE">Kurnik 2010</LINK>); whether or not to continue beyond childhood and the role of secondary prophylaxis in adult patients, etc. Similarly, several pharmacoeconomic evaluations have been published (<LINK REF="REF-Collins-2009" TYPE="REFERENCE">Collins 2009</LINK>; <LINK REF="REF-Miners-2009" TYPE="REFERENCE">Miners 2009</LINK>). Some of these studies have had a strong impact on the hemophilia community, and are likely to change the clinical practice in the western world. In low- and middle-income countries, studies are ongoing to evaluate the effectiveness of low-dose prophylaxis regimens.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-07-20 13:59:15 +0100" MODIFIED_BY="Tracey Remmington">
<IMPLICATIONS_PRACTICE MODIFIED="2011-07-20 13:59:15 +0100" MODIFIED_BY="Tracey Remmington">
<P>There is evidence from RCTs and observational studies that the use of prophylactic clotting factor concentrate is effective in decreasing the frequency of joint bleeds and in partially preventing or slowing down the development of arthropathy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-10-22 12:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>Future randomised clinical trials should address the following aspects:</P>
<OL>
<LI>comparative efficacy, safety and effectiveness of different prophylactic regimens (escalating versus fixed-dose, pharmacokinetic-tailored versus fixed-dose);</LI>
<LI>optimal starting and ending age;</LI>
<LI>standardized clinical and radiological outcome measures of efficacy;</LI>
<LI>long-term cost-effectiveness.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-07-15 14:10:44 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors would like to thank Ellen Crumley MLIS, for her literature searching and medical librarian support and Natasha Wiebe MSc, for her statistical support.</P>
<P>We would like to thank John K. Wu for his contribution to the original protocol.</P>
<P>The authors would also thank Louis Aledort, Mike Makris, Pier Mannuccio Mannucci, Claude Negrier for their helpful comments on draft versions of this review.</P>
<P>We are indebted to Kerry Dwan for repeatedly reading our review, providing statistical advice, checking most of our calculations, solving doubts and ultimately sensibly improving this systematic review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-10-22 11:56:31 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-07-20 12:47:57 +0100" MODIFIED_BY="Tracey Remmington">
<P>Kent Stobart: protocol development; study selection; data extraction; data entry; development of final review.</P>
<P>Alfonso Iorio: study selection; data extraction; development of final review.</P>
<P>John K. Wu (previous author): protocol development.</P>
<P>
<B>
<U>New roles in the update</U>
</B>
</P>
<P>Alfonso Iorio: updated manuscript drafting; development of final review.</P>
<P>Emanuela Marchesini: study selection; data extraction; updated manuscript drafting; development of final review.</P>
<P>Maura Marcucci: study selection; data extraction.</P>
<P>Anthony Chan: development of final review.</P>
<P>Kent Stobart: development of final review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-07-20 13:56:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>In the 2011 update we undertook a <I>post hoc </I> sensitivity analyse for adverse events.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-07-20 13:55:40 +0100" MODIFIED_BY="Tracey Remmington">
<STUDIES MODIFIED="2011-07-20 13:47:23 +0100" MODIFIED_BY="Tracey Remmington">
<INCLUDED_STUDIES MODIFIED="2011-07-20 13:34:23 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="PUB" ID="STD-Aronstam-1976" MODIFIED="2011-07-20 13:30:06 +0100" MODIFIED_BY="Tracey Remmington" NAME="Aronstam 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-07-20 13:30:06 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR, et al</AU>
<TI>Prophylaxis in hemophilia: a double-blind controlled trial</TI>
<SO>British Journal of Haematology</SO>
<YR>1976</YR>
<VL>33</VL>
<NO>1</NO>
<PG>81-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76184531"/>
<IDENTIFIER TYPE="OTHER" VALUE="50"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aronstam-1977" MODIFIED="2011-01-17 15:35:50 +0000" MODIFIED_BY="[Empty name]" NAME="Aronstam 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-01-17 15:35:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aronstam A, Kirk PJ, McHardy J, Culver-James JW, McLEllan DS, Turk P, et al</AU>
<TI>Twice weekly prophylactic therapy in haemophilia A</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>1977</YR>
<VL>30</VL>
<NO>1</NO>
<PG>65-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="117 (?112)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlsson-1997" NAME="Carlsson 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R</AU>
<TI>Improved cost-effectiveness by pharmacokinetic dosing of factor VIIII in prophylactic treatment of haemophilia A</TI>
<SO>Haemophilia</SO>
<YR>1997</YR>
<VL>3</VL>
<PG>96-101</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="64"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gringeri-2011" MODIFIED="2011-05-25 12:54:21 +0100" MODIFIED_BY="Tracey Remmington" NAME="Gringeri 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-05-25 12:54:21 +0100" MODIFIED_BY="Tracey Remmington" NOTES="&lt;p&gt;ESPRIT: Evaluation Study of Prophylaxis: a randomized Italian trial.&lt;/p&gt;" NOTES_MODIFIED="2011-05-25 12:54:21 +0100" NOTES_MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gringeri A, Lundin B, von Mackensen S, Mantovani LG, Mannucci PM and the ESPRIT study Group</AU>
<TI>A Randomized Clinical Trial of Prophylaxis in Children with Hemophilia A (the ESPRIT Study)</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>4</NO>
<PG>700-10</PG>
<IDENTIFIERS MODIFIED="2011-02-21 16:49:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-21 16:49:00 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1538-7836.2011.04214.x"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manco_x002d_Johnson-2007" MODIFIED="2010-10-08 15:36:55 +0100" MODIFIED_BY="[Empty name]" NAME="Manco-Johnson 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-07-09 16:35:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hacker MR, Page JH, Shapiro AD, Rich-Edwards JW, Manco-Johnson MJ</AU>
<TI>Central venous access device infections in children with hemophilia</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>7</NO>
<PG>458-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-08 15:36:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al</AU>
<TI>Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>6</NO>
<PG>535-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morfini-1976" MODIFIED="2011-07-20 13:34:23 +0100" MODIFIED_BY="Tracey Remmington" NAME="Morfini 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-07-20 13:34:23 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morfini M, Mannucci PM, Mariani G, Panicucci F, Petrucci F, Baicchi U, et al</AU>
<TI>Evaluation of prophylactic replacement therapy in haemophilia B</TI>
<SO>Scandinavian Journal of Haematology</SO>
<YR>1976</YR>
<VL>16</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76129390"/>
<IDENTIFIER TYPE="OTHER" VALUE="3"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-07-20 13:47:23 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="PUB" ID="STD-Aledort-1994" MODIFIED="2011-01-20 13:18:08 +0000" MODIFIED_BY="[Empty name]" NAME="Aledort 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-01-20 13:18:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aledort LM, Haschmeyer RH, Pettersson H, The orthopaedic outcome study group</AU>
<TI>A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1994</YR>
<VL>236</VL>
<NO>4</NO>
<PG>391-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Astermark-1999" MODIFIED="2011-07-20 13:40:28 +0100" MODIFIED_BY="Tracey Remmington" NAME="Astermark 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-07-20 13:40:28 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Astermark J, Petrini P, Tengbrorn L, Schulman S, Ljung R, Berntorp E</AU>
<TI>Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized</TI>
<SO>British Journal of Haematology</SO>
<YR>1999</YR>
<VL>105</VL>
<NO>4</NO>
<PG>1109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brackmann-1992" MODIFIED="2011-01-20 13:18:16 +0000" MODIFIED_BY="[Empty name]" NAME="Brackmann 1992" YEAR="1992">
<REFERENCE MODIFIED="0017-12-14 13:18:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U</AU>
<TI>Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience</TI>
<SO>Haemostasis</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>5</NO>
<PG>251-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chuansumrit-1995" MODIFIED="2010-10-08 15:40:08 +0100" MODIFIED_BY="[Empty name]" NAME="Chuansumrit 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-10-08 15:40:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chuansumrit A, Hathirat I, Hathirat P</AU>
<TI>Prophylactic treatment for haemophilia A patients:a pilot study</TI>
<SO>Southeast Asian Journal of Tropical Medicine of Public Health</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>2</NO>
<PG>243-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-2010" MODIFIED="2011-07-10 16:21:48 +0100" MODIFIED_BY="Alfonso Iorio" NAME="Collins 2010" YEAR="2009">
<REFERENCE MODIFIED="2011-07-10 16:21:48 +0100" MODIFIED_BY="Alfonso Iorio" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins P, Faradji A, Morfini M, Enriquez MM, Schwarz L</AU>
<TI>Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>1</NO>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Courter-2001" MODIFIED="2011-01-20 13:17:30 +0000" MODIFIED_BY="[Empty name]" NAME="Courter 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-01-20 13:17:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courter SG, Bedrosian CL</AU>
<TI>Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients</TI>
<SO>Seminars in Hematology</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>2</NO>
<PG>52-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dzinaj--1996" MODIFIED="2010-10-08 15:41:50 +0100" MODIFIED_BY="[Empty name]" NAME="Dzinaj  1996" YEAR="1996">
<REFERENCE MODIFIED="1975-07-03 15:41:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dzinaj T, Funk M, Schimdt H, Bottger S, Gngor T, Klarmann D, et al</AU>
<TI>Radiological score in paediatric haemophilic patients with early and late onset of factor VIII-prophylaxis</TI>
<SO>Thrombosis Haemostasis</SO>
<YR>1996</YR>
<VL>76</VL>
<NO>4</NO>
<PG>630-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldman-2006" MODIFIED="2010-10-08 15:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Feldman 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-08 15:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, et al</AU>
<TI>Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>6</NO>
<PG>1228-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-2005" MODIFIED="2010-10-08 15:44:53 +0100" MODIFIED_BY="[Empty name]" NAME="Fischer 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-01-20 12:19:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer K, Van Dijk K, Van Den Berg HM</AU>
<TI>Late prophylaxis for severe hemophilia: effects of prophylaxis started in adulthood [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>OR205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kavakli-1997" MODIFIED="2011-07-20 13:41:16 +0100" MODIFIED_BY="Tracey Remmington" NAME="Kavakli 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-07-20 13:41:16 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kavakli K, Nisli G, Aydinok Y, Oztop S, Cetingul N, Aydogdu S</AU>
<TI>Prophylactic therapy for hemophilia in a developing country, Turkey</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>2</NO>
<PG>151-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreuz-1998" MODIFIED="2011-01-20 13:18:00 +0000" MODIFIED_BY="[Empty name]" NAME="Kreuz 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-01-20 13:18:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreuz W, Escuriola-Ettinghausen C, Funk M, Schmidt H, Kornhuber B</AU>
<TI>When should prophylactic treatment in patients with haemophilia A and B start?- The German experience</TI>
<SO>Haemophilia</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>4</NO>
<PG>413-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liesner-1996" MODIFIED="2011-07-20 13:42:05 +0100" MODIFIED_BY="Tracey Remmington" NAME="Liesner 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-07-20 13:42:05 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liesner RJ, Khair K, Hann IM</AU>
<TI>The impact of prophylactic treatment in children with severe haemophilia</TI>
<SO>British Journal of Haematology</SO>
<YR>1996</YR>
<VL>92</VL>
<NO>4</NO>
<PG>973-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lofqvist-1997" MODIFIED="2011-07-20 13:33:10 +0100" MODIFIED_BY="Tracey Remmington" NAME="Lofqvist 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-07-20 13:33:10 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Löfqvist T, Nilsson IM, Berntorp E, Pettersson H</AU>
<TI>Haemophilia prophylaxis in young patients - a long-term follow-up</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1997</YR>
<VL>241</VL>
<NO>5</NO>
<PG>395-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manco_x002d_Johnson-1994" MODIFIED="2011-01-20 13:17:54 +0000" MODIFIED_BY="[Empty name]" NAME="Manco-Johnson 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-01-20 13:17:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R</AU>
<TI>Results of secondary prophylaxis in children with severe hemophilia</TI>
<SO>American Journal of Hematology</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>2</NO>
<PG>113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nemes-2007" MODIFIED="2009-12-14 10:12:18 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Nemes 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-12-14 10:12:13 +0000" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nemes L, Lissitchkov T, Klukowska A, Dobaczewski G, Komrska V, Aureswald G, et al</AU>
<TI>Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A</TI>
<SO>Haemophilia</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>9-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1970" MODIFIED="2011-07-20 13:42:42 +0100" MODIFIED_BY="Tracey Remmington" NAME="Nilsson 1970" YEAR="1970">
<REFERENCE MODIFIED="2011-07-20 13:42:42 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson IM, Blomback M, Ahlberg A</AU>
<TI>Our experience in Sweden with prophylaxis on haemophilia</TI>
<SO>Bibliotheca Hematologica</SO>
<YR>1970</YR>
<VL>34</VL>
<PG>111-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1976" MODIFIED="2011-02-22 07:12:38 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Nilsson 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-02-22 07:12:38 +0000" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson IM, Hedner U, Ahlberg A</AU>
<TI>Hemophilia prophylaxis in Sweden</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1976</YR>
<VL>65</VL>
<NO>2</NO>
<PG>129-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1992" MODIFIED="2011-07-20 13:44:20 +0100" MODIFIED_BY="Tracey Remmington" NAME="Nilsson 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-07-20 13:44:20 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson IM, Berntorp E, Löfqvist T, Pettersson H</AU>
<TI>Twenty-five years experience of prophylactic treatment in severe haemophilia A and B</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1992</YR>
<VL>232</VL>
<NO>1</NO>
<PG>25-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrini-1991" MODIFIED="2011-07-20 13:44:44 +0100" MODIFIED_BY="Tracey Remmington" NAME="Petrini 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-07-20 13:44:44 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrini P, Lindvall N, Egberg N, Blomback M</AU>
<TI>Prophylaxis with factor concentrates in preventing hemophilic arthropathy</TI>
<SO>American Journal of Pediatric Hematology/Oncology</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>3</NO>
<PG>280-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrini-2001" MODIFIED="2011-07-20 13:45:25 +0100" MODIFIED_BY="Tracey Remmington" NAME="Petrini 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-07-20 13:45:25 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrini P</AU>
<TI>What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?</TI>
<SO>Haemophilia</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>1</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettersson-1981" MODIFIED="2011-01-20 13:18:30 +0000" MODIFIED_BY="[Empty name]" NAME="Pettersson 1981" YEAR="1981">
<REFERENCE MODIFIED="2011-01-20 13:18:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pettersson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A</AU>
<TI>Radiologic evaluation of prophylaxis in severe haemophilia</TI>
<SO>Acta Paediatric of Scandinavia</SO>
<YR>1981</YR>
<VL>70</VL>
<NO>4</NO>
<PG>565-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsay-1973" MODIFIED="2010-10-08 15:49:10 +0100" MODIFIED_BY="[Empty name]" NAME="Ramsay 1973" YEAR="1973">
<REFERENCE MODIFIED="2010-10-08 15:49:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay DM, Parker AC</AU>
<TI>A trial of prophylactic replacement therapy in haemophilia and Christmas disease</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>1973</YR>
<VL>26</VL>
<NO>4</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Royal-2002" MODIFIED="2010-10-08 15:49:50 +0100" MODIFIED_BY="[Empty name]" NAME="Royal 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-08 15:49:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Royal S, Schramm W, Berntorp E, Giangrande P, Gringeri A, Ludlam C, et al</AU>
<TI>Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients</TI>
<SO>Haemophilia</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>1</NO>
<PG>44-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schimpf-1977" MODIFIED="2011-07-20 13:46:14 +0100" MODIFIED_BY="Tracey Remmington" NAME="Schimpf 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-07-20 13:46:14 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schimpf KI, Fisher B, Rothmann P</AU>
<TI>Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study</TI>
<SO>Scandinavian Journal of Haematology. Supplementum</SO>
<YR>1977</YR>
<VL>30</VL>
<PG>1979-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schobess-2008" MODIFIED="2011-07-20 13:47:23 +0100" MODIFIED_BY="Tracey Remmington" NAME="Schobess 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-07-20 13:47:23 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schobess R, Kurnik K, Friedrichs F, Halimeh S, Krümpel A, Bildingmaier C</AU>
<TI>Effect of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2008</YR>
<VL>99</VL>
<NO>1</NO>
<PG>71-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1996" MODIFIED="2010-10-08 15:50:14 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-10-08 15:50:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B</AU>
<TI>Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<NO>3</NO>
<PG>424-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szucs-1996" MODIFIED="2011-01-20 13:18:44 +0000" MODIFIED_BY="[Empty name]" NAME="Szucs 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-01-20 13:18:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szucs TD, Öffner A, Schramm W</AU>
<TI>Socioeconomic impact of haemophilia care: results of a pilot study</TI>
<SO>Haemophilia</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>4</NO>
<PG>211-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tagliaferri-2008" MODIFIED="2011-01-20 13:18:59 +0000" MODIFIED_BY="[Empty name]" NAME="Tagliaferri 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-01-20 13:18:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, et al</AU>
<TI>Effect of secondary prophylaxis started in adult and haemophiliacs</TI>
<SO>Haemophilia 
</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>5</NO>
<PG>945-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tusell-2002" MODIFIED="2011-01-20 13:18:48 +0000" MODIFIED_BY="[Empty name]" NAME="Tusell 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-01-20 13:18:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tusell J, Perez-Bianco R</AU>
<TI>Prophylaxis in developed and in emerging countries</TI>
<SO>Haemophilia</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-den-Berg-2001" MODIFIED="2011-01-20 13:19:06 +0000" MODIFIED_BY="[Empty name]" NAME="Van den Berg 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-01-20 13:19:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van den Berg HM, Fisher K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, et al</AU>
<TI>Long-term outcome of individualized prophylactic treatment of children with severe haemophilia</TI>
<SO>British Journal of Haematology</SO>
<YR>2001</YR>
<VL>112</VL>
<NO>3</NO>
<PG>561-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2011" MODIFIED="2011-07-10 16:27:26 +0100" MODIFIED_BY="Alfonso Iorio" NAME="Wu 2011" YEAR="2010">
<REFERENCE MODIFIED="2011-07-10 16:27:09 +0100" MODIFIED_BY="Alfonso Iorio" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu R, Luke KH, Poon M, Wu X, Zhang N, Zhao L, Su J, Zhang J</AU>
<TI>Low dose secondary prophylaxis reduces joint and severe bleeding in severe and moderate hemophilia children: A pilot study in China</TI>
<SO>Haemophilia</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>1</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-10-27 18:10:16 +0000" MODIFIED_BY="Emanuela Marchesini"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-07-20 13:55:40 +0100" MODIFIED_BY="Tracey Remmington">
<ADDITIONAL_REFERENCES MODIFIED="2011-07-20 13:55:40 +0100" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Ahlberg-1965" MODIFIED="2011-02-22 07:12:40 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Ahlberg 1965" TYPE="JOURNAL_ARTICLE">
<AU>Ahlberg A</AU>
<TI>Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B</TI>
<SO>Acta Orthopedic Scandinavian</SO>
<YR>1965</YR>
<VL>77</VL>
<NO>Suppl 1</NO>
<PG>7-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berntorp-2003" MODIFIED="2011-07-20 13:49:07 +0100" MODIFIED_BY="Tracey Remmington" NAME="Berntorp 2003" TYPE="JOURNAL_ARTICLE">
<AU>Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fisher K, Giangrande PL, et al</AU>
<TI>Consensus perspectives in prophylactic therapy for haemophilia: summary statement</TI>
<SO>Haemophilia</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blanchette-2004" MODIFIED="2011-07-20 13:49:17 +0100" MODIFIED_BY="Tracey Remmington" NAME="Blanchette 2004" TYPE="JOURNAL_ARTICLE">
<AU>Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R</AU>
<TI>Optimizing factor prophylaxis for the haemophilia population: where do we stand?</TI>
<SO>Haemophilia</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>Suppl 4</NO>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-2009" MODIFIED="2011-02-22 07:12:41 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Collins 2009" TYPE="JOURNAL_ARTICLE">
<AU>Collins PW, Bjorkman S, Fisher K, Blanchette V, Schroth P, Fritsch S, et al</AU>
<TI>Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>2</NO>
<PG>269-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2011-07-20 13:51:39 +0100" MODIFIED_BY="Tracey Remmington" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks J, Higgins J, Altman D</AU>
<TI>Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-2003" MODIFIED="2011-02-22 07:12:40 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Fisher 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fisher K, Van Den Berg M</AU>
<TI>Prophylaxis for severe haemophilia:clinical and economical issues</TI>
<SO>Haemophilia</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>376-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay-2007" MODIFIED="2011-02-22 07:12:40 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Hay 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hay CR</AU>
<TI>Prophylaxis in adults with haemophilia</TI>
<SO>Haemophilia</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>Suppl 2</NO>
<PG>10-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-07-10 16:34:25 +0100" MODIFIED_BY="Alfonso Iorio" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG</AU>
<TI>Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>[updated March 2011]</YR>
<PG>187-242</PG>
<EN>Version 5.1.0</EN>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hilgartner-1974" MODIFIED="2011-02-22 07:12:40 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Hilgartner 1974" TYPE="JOURNAL_ARTICLE">
<AU>Hilgartner MW</AU>
<TI>Hemophilic arthropathy</TI>
<SO>Advances in Pediatrics</SO>
<YR>1974</YR>
<VL>21</VL>
<PG>139</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurnik-2010" MODIFIED="2011-02-22 07:12:41 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Kurnik 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G</AU>
<TI>New early prophylaxis regimen that avoids immunological danger signals can reduceFVIII inhibitor development</TI>
<SO>Haemophilia</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>2</NO>
<PG>256-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ljiung-2000" MODIFIED="2011-07-20 13:53:54 +0100" MODIFIED_BY="Tracey Remmington" NAME="Ljiung 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ljiung R, Aranis-Vournas S, Kurnik-Auberger K, Van den Berg M, Chambost H, Claeyssens S</AU>
<TI>Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries</TI>
<SO>Haemophilia</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>6</NO>
<PG>619-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lusher-1997" MODIFIED="2011-02-22 07:12:40 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Lusher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lusher JM</AU>
<TI>Prophylaxis in children with hemophilia: is it the optimal treatment?</TI>
<SO>Thrombosis Haemostasis</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>1</NO>
<PG>726-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MASAC" MODIFIED="2011-07-20 13:55:15 +0100" MODIFIED_BY="Tracey Remmington" NAME="MASAC" TYPE="OTHER">
<AU>National Hemophilia Foundation. MASAC</AU>
<TI>MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding)</TI>
<SO>www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&amp;contentid=582</SO>
<YR>(accessed 01 July 2010)</YR>
<NO>Document 107</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miners-2004" MODIFIED="2011-07-20 13:55:24 +0100" MODIFIED_BY="Tracey Remmington" NAME="Miners 2004" TYPE="JOURNAL_ARTICLE">
<AU>Miners A, Lee CA</AU>
<TI>Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia A</TI>
<SO>Haemophilia</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>58-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miners-2009" MODIFIED="2011-02-22 07:12:41 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Miners 2009" TYPE="JOURNAL_ARTICLE">
<AU>Miners A</AU>
<TI>Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A</TI>
<SO>Haemophilia</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>881-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHF-1994" MODIFIED="2011-07-20 13:55:40 +0100" MODIFIED_BY="Tracey Remmington" NAME="NHF 1994" TYPE="OTHER">
<AU>The National Hemophilia Foundation</AU>
<TI>Medical and Scientific Advisory Council recommendations concerning prophylaxis [abstract]</TI>
<SO>Medical Bulletin</SO>
<YR>1994</YR>
<VL>No.193, Chapter Advisory No.197</VL>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-05-25 12:45:25 +0100" MODIFIED_BY="Tracey Remmington" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teitel-2004" MODIFIED="2011-02-22 07:12:40 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="Teitel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Teitel JM, Barnard D, Israels SJ, Lillicrap D, Poon MC, Sek J</AU>
<TI>Home care management of haemophilia</TI>
<SO>Haemophilia</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>2</NO>
<PG>118-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14962201"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-den-Berg-2002" MODIFIED="2011-02-22 07:12:40 +0000" MODIFIED_BY="Emanuela Marchesini" NAME="van den Berg 2002" TYPE="JOURNAL_ARTICLE">
<AU>van den Berg HM, Fischer K, van der Born JG, Roosendaal G, Mauser-Bunschoten EP</AU>
<TI>Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies</TI>
<SO>Haemophilia</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>S2</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-07-20 13:23:37 +0100" MODIFIED_BY="Tracey Remmington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-07-20 13:23:08 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-10-22 11:12:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aronstam-1976">
<CHAR_METHODS MODIFIED="2010-10-08 15:31:13 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study.<BR/>Time unit: school term.<BR/>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-08 15:32:38 +0100" MODIFIED_BY="[Empty name]">
<P>Country: England.<BR/>Participants: males with hemophilia A.<BR/>(factor VIII &lt; 1%).<BR/>Age Range: 13 - 17 years.<BR/>Number enrolled: 9.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 11:12:28 +0100" MODIFIED_BY="[Empty name]">
<P>Factor VIII concentrate.<BR/>(Blood Products Laboratory - UK).<BR/>Arm A: 0.25 U/kg once weekly.<BR/>Arm B: 0.01 U/kg once weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-08 15:32:11 +0100" MODIFIED_BY="[Empty name]">
<P>Bleeding events or frequency.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-18 06:29:30 +0100" MODIFIED_BY="Emanuela Marchesini"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-19 14:13:51 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Aronstam-1977">
<CHAR_METHODS MODIFIED="2010-10-22 11:12:06 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study.<BR/>Time unit: school term.<BR/>Randomized clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-05-19 14:13:51 +0100" MODIFIED_BY="Tracey Remmington">
<P>Country: England.<BR/>Participants: males with hemophilia A (factor VIII &lt; 1%).<BR/>Age Range: 13 - 17 years.<BR/>Number enrolled: 4.</P>
<P>All patients completed the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-08 15:31:52 +0100" MODIFIED_BY="[Empty name]">
<P>Cryoprecipitate (prepared by Wessex Regional Transfusion Centre) or Kryobulin (prepared by Serological Products, UK).<BR/>Arm A: raise factor VIII to 15% twice weekly.<BR/>Arm B: raise factor VIII to 30% twice weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-08 15:31:49 +0100" MODIFIED_BY="[Empty name]">
<P>Bleeding events or frequency.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-18 06:29:30 +0100" MODIFIED_BY="Emanuela Marchesini"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-22 11:12:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carlsson-1997">
<CHAR_METHODS MODIFIED="2010-10-22 11:12:17 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study.<BR/>1-year duration.<BR/>Time unit: 6 months.<BR/>Randomized clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-08 15:31:36 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Sweden.<BR/>Participants: samples with clinically severe hemophilia A (factor VIII &lt; 2%).<BR/>Age range: 8 - 42 years.<BR/>Number enrolled: 21.<BR/>Number completed: 14.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-08 15:31:32 +0100" MODIFIED_BY="[Empty name]">
<P>Factor VIII concentrate (monoclonal antibody plasma derived, high-purity plasma-derived, or recombinant).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-08 15:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>Bleeding events or frequency.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-18 06:29:30 +0100" MODIFIED_BY="Emanuela Marchesini"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-20 13:20:06 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Gringeri-2011">
<CHAR_METHODS MODIFIED="2010-10-08 15:31:13 +0100" MODIFIED_BY="[Empty name]">
<P>10 years duration.</P>
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-08 15:31:11 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy.</P>
<P>Participants: male with severe hemophilia A (factor VIII level &lt;1%).</P>
<P>Median age: 4 years (age less than 7 years).</P>
<P>Number enrolled: 40.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-20 13:20:06 +0100" MODIFIED_BY="Tracey Remmington">
<P>Recombinant factor VIII concentrate (Recombinate).</P>
<P>Arm A:25 IU per kilogram of body weight 3 times a week.<BR/>Arm B: 25 IU per kilogram of body weight until complete healing.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-08 15:31:00 +0100" MODIFIED_BY="[Empty name]">
<P>Joint deterioration, bleed frequency.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-26 11:24:46 +0000" MODIFIED_BY="Emanuela Marchesini"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-20 13:21:00 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Manco_x002d_Johnson-2007">
<CHAR_METHODS MODIFIED="2011-07-20 13:20:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>9 years duration.</P>
<P>Time unit: mean 49 month (48-58 month).</P>
<P>Multicentre, open-label trial randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-08 15:30:39 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA.</P>
<P>Participants: male with severe and moderate-severe hemophilia A (factor VIII level &lt;2%).</P>
<P>Age: mean 1.6 years (age less than 30 month in all participants).</P>
<P>Number enrolled: 65.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-20 13:21:00 +0100" MODIFIED_BY="Tracey Remmington">
<P>Recombinant factor VIII concentrate (Kogenate or Kogenate Bayer).</P>
<P>Arm A: 25 IU of factor VIII per kilogram of body weight every other day to prevent bleeding. When hemarthroses occurred during prophylaxis, patients were treated with 40 IU per kg at the time of joint haemorrhage.</P>
<P>Arm B: 40 IU per kg of body weight at the time of joint haemorrhage and 20 IU at 24 hours and 72 hours after the first dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-08 15:30:41 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: preservation of index-joint structure.</P>
<P>Secondary outcomes: number of bleeding events, number of infusion, total of factor VIII units administrated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-20 13:23:08 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Morfini-1976">
<CHAR_METHODS MODIFIED="2011-07-20 13:23:08 +0100" MODIFIED_BY="Tracey Remmington">
<P>Cross-over study.<BR/>1 year duration.<BR/>Time unit: 3-month cycles (A-B-A-B versus B-A-B-A).<BR/>Randomized clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-08 15:32:38 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy.<BR/>Participants: males with hemophilia B (factor IX &lt; 1%).<BR/>Age range: 5 - 45 years.<BR/>Number enrolled: 10.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-08 15:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>Factor IX concentrate (Bebulin).<BR/>Arm A: 7.5 U/kg twice weekly.<BR/>Arm B: 15 U/kg weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-08 15:32:48 +0100" MODIFIED_BY="[Empty name]">
<P>Bleeding events or frequency, joint deterioration.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-18 06:29:32 +0100" MODIFIED_BY="Emanuela Marchesini"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IU: international units</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-07-20 13:23:37 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-02-12 17:47:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aledort-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-22 10:56:01 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Astermark-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:16 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brackmann-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chuansumrit-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:19 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-22 11:57:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collins-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-22 11:57:27 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational cross-over study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Courter-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:24 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dzinaj--1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio" STUDY_ID="STD-Feldman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio">
<P>Prospective observational single-arm dose-escalation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fischer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:42 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kavakli-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:42 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kreuz-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:40 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:29:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liesner-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:29:40 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:34:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lofqvist-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:34:14 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:34:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manco_x002d_Johnson-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:34:14 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio" STUDY_ID="STD-Nemes-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio">
<P>Prospective observational single arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-12 17:47:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilsson-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-17 08:25:19 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study with historical control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-19 14:12:18 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Nilsson-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-19 14:12:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>Prospective observational study with historical control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 14:55:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilsson-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-12 18:38:46 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-20 13:23:27 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Petrini-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-20 13:23:27 +0100" MODIFIED_BY="Tracey Remmington">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:34:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petrini-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:34:11 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:34:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettersson-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:34:09 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study with historical control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:34:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ramsay-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio" STUDY_ID="STD-Royal-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio">
<P>Retrospective observational study with parallel groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-20 13:23:37 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Schimpf-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-20 13:23:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>Prospective observational cross-over study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:34:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schobess-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:34:52 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio" STUDY_ID="STD-Smith-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio">
<P>Retrospective observational switch study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:35:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Szucs-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:35:12 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio" STUDY_ID="STD-Tagliaferri-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-10 16:20:47 +0100" MODIFIED_BY="Alfonso Iorio">
<P>Retrospective observational switch study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-08 15:35:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tusell-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-08 15:35:18 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-19 14:12:11 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Van-den-Berg-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-19 14:12:11 +0100" MODIFIED_BY="Tracey Remmington">
<P>Retrospective observational single-arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-19 14:12:04 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Wu-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-19 14:12:04 +0100" MODIFIED_BY="Tracey Remmington">
<P>Prospective observation with historical control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-10-27 18:10:16 +0000" MODIFIED_BY="Emanuela Marchesini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-07-20 13:21:59 +0100" MODIFIED_BY="Tracey Remmington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-05-19 14:13:45 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:32:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aronstam-1976">
<DESCRIPTION>
<P>The authors did not specify sequence generation methods but specified that it was generated by the Wessex Medical Information Unit.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-19 14:13:45 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Aronstam-1977">
<DESCRIPTION>
<P>The authors reported they used a random sequence generation but did not give details about methods of sequence generation: Quote:" The boys were allocated to different treatment schedules at random at the start of the trial.....".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:31:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1997">
<DESCRIPTION>
<P>Published report specifies that is a random sequence generation but not defines methods of sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-19 14:13:22 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Gringeri-2011">
<DESCRIPTION>
<P>Quote: " centralized allocation system based on a computer generated randomization list.....".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:30:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manco_x002d_Johnson-2007">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:29:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morfini-1976">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-10-22 11:40:17 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:32:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronstam-1976">
<DESCRIPTION>
<P>Quote:"...the random allocation of trial subjects to the different regimens at the beginning of each trial term was made by the Wessex Medical Information Unit".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:31:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aronstam-1977">
<DESCRIPTION>
<P>The authors did not specify methods of concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:31:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1997">
<DESCRIPTION>
<P>The authors did not specify methods of concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:30:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gringeri-2011">
<DESCRIPTION>
<P>Quote: " patients were centrally randomised to be treated on prophylaxis with.....".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 11:40:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manco_x002d_Johnson-2007">
<DESCRIPTION>
<P>Quote: "randomisation was performed centrally and stratified by site in permuted blocks of 2, 4 or 6."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:29:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morfini-1976">
<DESCRIPTION>
<P>Quote:" allocation to treatment protocols was made on the basis of random envelopes.....".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-07-20 13:20:19 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2" REF_IDS="CMP-001.02">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-07-20 13:19:00 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Aronstam-1976">
<DESCRIPTION>
<P>Patients were blinded to the assignment treatment; clinicians and assessors were unblinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-07-20 13:19:30 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Aronstam-1977">
<DESCRIPTION>
<P>Patients and clinicians were blinded to the assignment treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-08 15:31:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carlsson-1997">
<DESCRIPTION>
<P>No blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-07-20 13:20:19 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Gringeri-2011">
<DESCRIPTION>
<P>Patients were unblinded, but the outcome assessors (for musculoskeletal and radiologic evaluation) were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-07-10 14:41:42 +0100" MODIFIED_BY="Alfonso Iorio" RESULT="YES" STUDY_ID="STD-Manco_x002d_Johnson-2007">
<DESCRIPTION>
<P>Quote: "The radiologists who reviewed joint images, the physiotherapists who performed assays were unaware of the patients' treatment assignments and status with respect to a history of bleeding".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-08 15:29:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morfini-1976">
<DESCRIPTION>
<P>No blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-07-20 13:21:22 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2" REF_IDS="CMP-001.02">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-02-17 09:48:51 +0000" MODIFIED_BY="emanuela marchesini " RESULT="YES" STUDY_ID="STD-Aronstam-1976">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-08 15:31:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronstam-1977">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-08 15:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlsson-1997">
<DESCRIPTION>
<P>Reason of withdrawal were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-05-19 14:13:16 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Gringeri-2011">
<DESCRIPTION>
<P>Missing data have been in managed intention-to-treat analysis by last observation carried forward technique. List of cause for withdrawal: 9 patients refused randomization; 3 patients suffered for more than 2 bleeding episodes in the same joints; 3 patients had not bled in the previous 6 months, 1 child had radiologic signs of arthropathy, 1 child belonged to an unreliable (dysfunctional) family.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-07-20 13:21:22 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Manco_x002d_Johnson-2007">
<DESCRIPTION>
<P>Missing data have been managed in intention-to-treat analysis by last observation carried forward technique. Patients removed in by protocol analysis: 5/32 (list of causes for withdrawal: 2 patients developed high titre inhibitors; 1 patient had joint damage; 2 patients dropped out) in the prophylaxis group and 11/33 (list of causes for withdrawal: 3 for life threatening haemorrhage; 6 patients had joint damage; 1 patient dropped out; 1 was lost to follow up) in the on-demand group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-08 15:29:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morfini-1976">
<DESCRIPTION>
<P>No missing data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-10-22 09:06:14 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:32:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronstam-1976">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:31:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronstam-1977">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:31:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlsson-1997">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:30:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gringeri-2011">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 09:06:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manco_x002d_Johnson-2007">
<DESCRIPTION>
<P>The study protocol is published at the end of enrolment but the published reports include all expected outcomes and analysed data following protocol publication. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:29:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morfini-1976">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-07-20 13:21:59 +0100" MODIFIED_BY="Tracey Remmington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 13:19:11 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Aronstam-1976">
<DESCRIPTION>
<P>Cross-over study without washout period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 13:19:38 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Aronstam-1977">
<DESCRIPTION>
<P>Cross-over study without washout period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 13:19:57 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1997">
<DESCRIPTION>
<P>Cross-over study without washout period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-10 16:20:05 +0100" MODIFIED_BY="Alfonso Iorio" RESULT="NO" STUDY_ID="STD-Gringeri-2011">
<DESCRIPTION>
<P>Significant degree of cross-over between treatment arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 15:30:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manco_x002d_Johnson-2007">
<DESCRIPTION>
<P>No risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 13:21:59 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Morfini-1976">
<DESCRIPTION>
<P>Cross-over study without washout period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-07-20 14:00:06 +0100" MODIFIED_BY="Tracey Remmington">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-07-20 14:00:06 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<TITLE MODIFIED="2010-10-22 11:34:30 +0100" MODIFIED_BY="[Empty name]">Additional non-randomised observational clinical studies</TITLE>
<TABLE COLS="6" ROWS="32">
<TR>
<TD>
<P>Study ID</P>
</TD>
<TD>
<P>Methods</P>
</TD>
<TD>
<P>Participants</P>
</TD>
<TD>
<P>Interventions</P>
</TD>
<TD>
<P>Outcomes</P>
</TD>
<TD>
<P>Notes</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aledort-1994" TYPE="STUDY">Aledort 1994</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study.</P>
</TD>
<TD>
<P>Country: Japan, USA, Europe. Cases: severe hemophilia A, under age 25 years. Enrolled 66; controls 411.</P>
</TD>
<TD>
<P>Dose category in mcg/kg body weight per year.</P>
</TD>
<TD>
<P>Orthopedic joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Astermark-1999" TYPE="STUDY">Astermark 1999</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: severe hemophilia A and B. Hemophilia A = 108; Hemophilia B = 13.</P>
</TD>
<TD>
<P>Clotting factor concentrates 25-40 IU/kg body weight. Hemophilia A: three times per week. Hemophilia B: 2 times per week.</P>
</TD>
<TD>
<P>Bleeding episodes. Orthopedic joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brackmann-1992" TYPE="STUDY">Brackmann 1992</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study.</P>
</TD>
<TD>
<P>Country: Germany. Cases: severe hemophilia A, &lt;16 years of age in 1978. Number enrolled: 90.</P>
</TD>
<TD>
<P>Clotting factor concentrate: no details provided.</P>
</TD>
<TD>
<P>Bleeding episodes. Clinical joint score. Radiological joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chuansumrit-1995" TYPE="STUDY">Chuansumrit 1995</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study. Single arm.</P>
</TD>
<TD>
<P>Country: Thailand. Cases: moderate and severe hemophilia A. Number enrolled: 6.</P>
</TD>
<TD>
<P>Clotting factor concentrate 8-10 U/kg body weight twice per week.</P>
</TD>
<TD>
<P>Bleeding episodes. Days of hospitalisation.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Collins-2010" TYPE="STUDY">Collins 2010</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study. Cross-over study</P>
</TD>
<TD>
<P>Country: United States, UK. Case: severe hemophilia. Enrolled: 20</P>
</TD>
<TD>
<P>rFVIII-FS</P>
</TD>
<TD>
<P>Bleeding episodes, joint function, health related QoL, health economics and safety</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Courter-2001" TYPE="STUDY">Courter 2001</LINK>
</P>
</TD>
<TD>
<P>Prospective observational label study.</P>
</TD>
<TD>
<P>Country: Multinational. Cases: severe hemophilia A. Previously untreated patients. Enrolled: 27.</P>
</TD>
<TD>
<P>Coagulation recombinant factor BDDrFVIII. Prophylaxis or on-demand therapy.</P>
</TD>
<TD>
<P>Bleeding episodes.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dzinaj--1996" TYPE="STUDY">Dzinaj 1996</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study.</P>
</TD>
<TD>
<P>Country: Germany. Cases: early onset prophylaxis versus late onset of prophylaxis in moderate or severe hemophilia A). Enrolled: Cases = 10. Controls = 7.</P>
</TD>
<TD>
<P>Clotting factor concentrate (Humate P) 30-40 IU/kg body weight three times per week.</P>
</TD>
<TD>
<P>Radiologic joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Feldman-2006" TYPE="STUDY">Feldman 2006</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study. Single arm dose escalation.</P>
</TD>
<TD>
<P>Country: Canada. Cases: severe hemophilia A. Enrolled: 25</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
<P>Step1 prophylaxis with 50 IU/kg/weekly</P>
<P>Step 2 prophylaxis with 30 IU/kg twice a week if patients met excalation criteria</P>
<P>Step 3 25 IU/kg on alternative days if patients met excalation criteria</P>
<P/>
</TD>
<TD>
<P>Bleeding episodes.</P>
</TD>
<TD>
<P>excalation criteria:</P>
<P>- target joint development</P>
<P>- four or more bleeding episodes in a consecutive 3-month period</P>
<P>- more than 5 joint bleeding in any period of time</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fischer-2005" TYPE="STUDY">Fischer 2005</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study.</P>
</TD>
<TD>
<P>Country: Netherlands. Cases: severe hemophilia A. Enrolled: 61.</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
</TD>
<TD>
<P>Joint bleeds.</P>
<P>Radiological joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kavakli-1997" TYPE="STUDY">Kavakli 1997</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study, both historically and parallel group controlled.</P>
</TD>
<TD>
<P>Country: Turkey. cases: 6 with severe hemophilia A, 1 with severe hemophilia B. Controls = 10.</P>
</TD>
<TD>
<P>Clotting factor concentrate. 20-50 IU/kg body weight twice weekly.</P>
</TD>
<TD>
<P>Vital bleeds. Joint bleeds. Days hospitalised. Orthopedic score. Radiologic joint score. Life quality.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kreuz-1998" TYPE="STUDY">Kreuz 1998</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study.</P>
</TD>
<TD>
<P>Country: Germany. Cases: previously untreated patients with moderate or severe hemophilia A. Enrolled: 21.</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
</TD>
<TD>
<P>Joint bleeding.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Liesner-1996" TYPE="STUDY">Liesner 1996</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study. Single arm.</P>
</TD>
<TD>
<P>Country: UK. Cases: severe hemophilia A and B. Enrolled 24 and 3, respectively.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Prophylaxis regimen.</P>
</TD>
<TD>
<P>Number of bleeding episodes.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lofqvist-1997" TYPE="STUDY">Lofqvist 1997</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: severe hemophilia A or B. Enrolled: hemophilia A = 29. Hemophilia B = 5.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Dose: 25-40 IU/kg body weight. Hemophilia A three times per week. Hemophilia B twice per week.</P>
</TD>
<TD>
<P>Orthopedic joint scores. Radiologic joint scores.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Manco_x002d_Johnson-1994" TYPE="STUDY">Manco-Johnson 1994</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study.</P>
</TD>
<TD>
<P>Country: USA. Cases: severe hemophilia A and B. Enrolled: hemophilia A = 13; hemophilia B = 1.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Dose: factor VIII 20 IU/kg body weight. factor IX 40 IU/kg body weight. Frequency: Factor VIII three times per week (n = 6), and every other day (n = 7). Factor IX twice per week.</P>
</TD>
<TD>
<P>Bleeding episodes. Radiologic joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nilsson-1970" TYPE="STUDY">Nilsson 1970</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational with historical control.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: 24 with hemophilia A.</P>
</TD>
<TD>
<P>AHF freeze-dried concentrate.</P>
</TD>
<TD>
<P>Days of hospitalisation.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nilsson-1976" TYPE="STUDY">Nilsson 1976</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational with historical control.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: 29 with hemophilia A.</P>
</TD>
<TD>
<P>AHF freeze-dried concentrate.</P>
</TD>
<TD>
<P>Orthopedic joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nilsson-1992" TYPE="STUDY">Nilsson 1992</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: severe hemophilia A or B. Enrolled: hemophilia A = 52. hemophilia B = 8.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Dose: Hemophilia A 24-40 IU/kg body weight three time per week. Hemophilia B 25-40 IU/kg body weight twice weekly.</P>
</TD>
<TD>
<P>Orthopedic joint score. Radiologic joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nemes-2007" TYPE="STUDY">Nemes 2007</LINK>
</P>
</TD>
<TD>
<P>Prospective, multicenter, 3-part clinical trial.</P>
</TD>
<TD>
<P>Country: Austria. Cases: severe hemophilia A. Enrolled: cases 49. Control 17</P>
</TD>
<TD>
<P>Immunate S/D. Dose: according to pharmacokinetics evaluation</P>
</TD>
<TD>
<P>Bleeding frequency.</P>
</TD>
<TD>
<P>Part 1:pharmacokinetics randomised double-blind;</P>
<P>Part 2: prospective observational study.Subjects received infusions with Immunate S/D</P>
<P>Part 3: pharmacokinetics evaluation after 14 weeks +/- 7 days</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Petrini-1991" TYPE="STUDY">Petrini 1991</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: severe hemophilia A born in 1965 - 1972 treated initially on-demand. Controls: severe hemophilia A born 1976 - 1983 treated prophylactically. Enrolled: Cases: 7. Controls: 7.</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
</TD>
<TD>
<P>Bleed frequency. Limitation of joint movement. Ankle hemarthrosis.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Petrini-2001" TYPE="STUDY">Petrini 2001</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study. Historical control.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: severe hemophilia A or B, born 1988-1998. Enrolled: 34.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Dose: 20-40 IU/kg body weight. Hemophilia A three times per week. Hemophilia B twice per week.</P>
</TD>
<TD>
<P>Joint bleeds. Hemarthrosis.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pettersson-1981" TYPE="STUDY">Pettersson 1981</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study. Historical control.</P>
</TD>
<TD>
<P>Country: Sweden. Cases: 44 with severe hemophilia A. 6 with severe hemophilia B.</P>
</TD>
<TD>
<P>Hemophilia A: AHF-Kabi. Hemophilia B: Preconativ (KabiVitrum).</P>
</TD>
<TD>
<P>Radiological joint score.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ramsay-1973" TYPE="STUDY">Ramsay 1973</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study.</P>
</TD>
<TD>
<P>Country: UK. Cases: severe hemophilia A or B. Enrolled: Hemophilia A = 2, Hemophilia B =1.</P>
</TD>
<TD>
<P>Clotting factor concentrate: cryoprecipitate.</P>
</TD>
<TD>
<P>Bleeding episodes.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Royal-2002" TYPE="STUDY">Royal 2002</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study. Parallel groups.</P>
</TD>
<TD>
<P>Country: Europe. Cases: prophylaxis regimen (varies between HTC). Controls: on-demand. Enrolled: Cases: 313. Controls: 590.</P>
</TD>
<TD>
<P>Clotting factor concentrate in prophylactic or on-demand regimen.</P>
</TD>
<TD>
<P>QoL Instrument: SF-36.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schimpf-1977" TYPE="STUDY">Schimpf 1977</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study. Cross-over study.</P>
</TD>
<TD>
<P>Country: Germany. Cases: severe hemophilia A. Enrolled: 6.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Treatment A: 1 x 36 U/kg body weight and week. Treatment B: 2 x 18 U/kg body weight and week. Treatment C: 3 x 12 U/kg body weight and week.</P>
</TD>
<TD>
<P>Bleeding episodes.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schobess-2008" TYPE="STUDY">Schobess 2008</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study.</P>
</TD>
<TD>
<P>Country: Germany. Cases: Preaviously untreated patients with severe hemophilia A. Enrolled: 109 (42 primary prophylaxis: 67 secondary prophylaxis).</P>
</TD>
<TD>
<P>At discretion of the participating centre. Median 40 IU/kg twice a week.</P>
</TD>
<TD>
<P>Bleeding episodes</P>
<P>Joint preservation</P>
<P>Development of target joint</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Smith-1996" TYPE="STUDY">Smith 1996</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational switch study.</P>
</TD>
<TD>
<P>Country: USA. Cases: episodic infusions. Controls: prophylactic infusions. Enrolled: 27. Controls = 70.</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
</TD>
<TD>
<P>Bleeding episodes. Incremental cost effectiveness.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Szucs-1996" TYPE="STUDY">Szucs 1996</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study.</P>
</TD>
<TD>
<P>Country: Germany. Cases: moderate or severe hemophilia. Number enrolled: moderate = 4, severe = 46.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Treatment programs: (i) on-demand; (ii) pure prophylaxis; (iii) modified prophylaxis.</P>
</TD>
<TD>
<P>Joint bleeds. QoL (SF-36). Cost of care. Cost effectiveness.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tagliaferri-2008" TYPE="STUDY">Tagliaferri 2008</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational switch study.</P>
</TD>
<TD>
<P>Country: Italy. Cases: adolescents and adults severe hemophilia patients.Number enrolled= 84</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
</TD>
<TD>
<P>Joint bleeds. Orthopedic and radiologic score, QoL, days lost from work/school, usage of clotting factor concentrates</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tusell-2002" TYPE="STUDY">Tusell 2002</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study.</P>
</TD>
<TD>
<P>Country: Spain. Cases: severe hemophilia A or B. Enrolled: Hemophilia A = 423. Hemophilia B = 88.</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
</TD>
<TD>
<P>Bleeding episodes.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Van-den-Berg-2001" TYPE="STUDY">Van den Berg 2001</LINK>
</P>
</TD>
<TD>
<P>Retrospective observational study. Single arm.</P>
</TD>
<TD>
<P>Country: Netherlands. Case: severe hemophilia A or B. Enrolled: hemophilia A = 70. hemophilia B = 5.</P>
</TD>
<TD>
<P>Clotting factor concentrate.</P>
</TD>
<TD>
<P>Bleeding episodes.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wu-2011" TYPE="STUDY">Wu 2011</LINK>
</P>
</TD>
<TD>
<P>Prospective observational study. Single arm.</P>
</TD>
<TD>
<P>Country: China. Case: severe and moderate hemophilia. Enrolled: Hemophilia A = 34.</P>
</TD>
<TD>
<P>Clotting factor concentrate. Low dose (10 IU/kg/x2 week)</P>
</TD>
<TD>
<P>Bleeding episodes.</P>
<P>Cost effectiveness.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>IU: international units<BR/>QoL: quality of life</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-07-20 11:52:20 +0100" MODIFIED_BY="Tracey Remmington">
<COMPARISON ID="CMP-001" MODIFIED="2011-07-20 11:43:10 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>Standard prophylaxis versus placebo (factor VIII concentrate (post-infusion level)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-07-20 11:42:27 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="59.93" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Bleed frequency</NAME>
<GROUP_LABEL_1>Wkly 0.25IU/mL</GROUP_LABEL_1>
<GROUP_LABEL_2>Wkly 0.01IU/mL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours wkly 0.25IU/mL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours wkly 0.01IU/mL</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate difference</EFFECT_MEASURE>
<IV_DATA CI_END="-4.908906965916039" CI_START="-16.551093034083962" EFFECT_SIZE="-10.73" ESTIMABLE="YES" ESTIMATE="-10.73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-14 12:05:25 +0100" MODIFIED_BY="[Empty name]" ORDER="9167" SE="2.97" STUDY_ID="STD-Aronstam-1976" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-07-20 11:43:10 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="16.18" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Morbidity (length of stay)</NAME>
<GROUP_LABEL_1>Wkly 0.25IU/mL</GROUP_LABEL_1>
<GROUP_LABEL_2>Wkly 0.01IU/mL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours wkly 0.25IU/mL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours wkly 0.01IU/mL</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.3960486849732169" CI_START="0.20315584876887946" EFFECT_SIZE="0.2836540264997704" ESTIMABLE="YES" ESTIMATE="-1.26" LOG_CI_END="-0.40225142438860734" LOG_CI_START="-0.6921706700075873" LOG_EFFECT_SIZE="-0.5472110471980973" ORDER="9168" SE="0.1703" STUDY_ID="STD-Aronstam-1976" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-07-20 11:47:25 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<NAME>Standard prophylaxis versus on-demand treatment (factor VIII concentrate)</NAME>
<IV_OUTCOME CHI2="196.7751701125781" CI_END="0.7626417185077152" CI_START="0.11680614102696131" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.2984647988039064" ESTIMABLE="YES" I2="99.49180580078885" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.1176794413622032" LOG_CI_START="-0.9325343237988523" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.5251068825805276" MODIFIED="2011-07-20 11:37:29 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="9.992007221626409E-16" P_Q="1.0" P_Z="0.011534622060611727" Q="0.0" RANDOM="YES" SCALE="275.13" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.4558830399999999" TOTALS="YES" TOTAL_1="48" TOTAL_2="48" WEIGHT="100.0" Z="2.5260708380720835">
<NAME>Bleed frequency</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>On demand</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours on demand</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.5244288201475662" CI_START="0.4420402093217302" EFFECT_SIZE="0.48147546711372347" ESTIMABLE="YES" ESTIMATE="-0.7309" LOG_CI_END="-0.28031344953891907" LOG_CI_START="-0.3545382241072545" LOG_EFFECT_SIZE="-0.3174258368230868" MODIFIED="2011-06-15 13:32:07 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.0436" STUDY_ID="STD-Gringeri-2011" TOTAL_1="21" TOTAL_2="19" WEIGHT="50.046664571346724"/>
<IV_DATA CI_END="0.20488593059952065" CI_START="0.16677692979774567" EFFECT_SIZE="0.18485195823723924" ESTIMABLE="YES" ESTIMATE="-1.6882" LOG_CI_END="-0.6884878633302897" LOG_CI_START="-0.7778640253678497" LOG_EFFECT_SIZE="-0.7331759443490697" MODIFIED="2011-06-15 13:32:07 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.0525" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="27" TOTAL_2="29" WEIGHT="49.95333542865328"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="63.31268682411613" CI_END="0.6346796279880593" CI_START="0.07724696808354477" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.22142058839789422" ESTIMABLE="YES" I2="98.4205377308058" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.19744544149124726" LOG_CI_START="-1.1121185574749937" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6547819994831204" MODIFIED="2011-07-20 11:46:23 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="1.7763568394002505E-15" P_Q="1.0" P_Z="0.005013933580818258" Q="0.0" RANDOM="YES" SCALE="51.64" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.56826304" TOTALS="YES" TOTAL_1="21" TOTAL_2="0" WEIGHT="100.0" Z="2.8061372183914615">
<NAME>Joint bleeding</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>On demand</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours on demand</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.4309710149446948" CI_START="0.33038866059681776" EFFECT_SIZE="0.37734326068399426" ESTIMABLE="YES" ESTIMATE="-0.9746" LOG_CI_END="-0.36555193743294195" LOG_CI_START="-0.4809748666928765" LOG_EFFECT_SIZE="-0.4232634020629092" MODIFIED="2011-05-27 14:21:57 +0100" MODIFIED_BY="Tracey Remmington" ORDER="30" SE="0.0678" STUDY_ID="STD-Gringeri-2011" TOTAL_1="21" TOTAL_2="0" WEIGHT="50.391655390780926"/>
<IV_DATA CI_END="0.16198100453108633" CI_START="0.10247629316041877" EFFECT_SIZE="0.1288379327168312" ESTIMABLE="YES" ESTIMATE="-2.0492" LOG_CI_END="-0.7905359120686484" LOG_CI_START="-0.9893765925636387" LOG_EFFECT_SIZE="-0.8899562523161436" MODIFIED="2011-05-27 14:21:57 +0100" MODIFIED_BY="Tracey Remmington" ORDER="29" SE="0.1168" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="49.608344609219074"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="42" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-20 11:46:52 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.26" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="49" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Joint function protection</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>On demand</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours on demand</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prophylaxis</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="25" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-08 15:59:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Primary prophylaxis</NAME>
<DICH_DATA CI_END="1.0132995992219354" CI_START="0.3867004007780646" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 08:28:00 +0000" MODIFIED_BY="Alfonso Iorio" ORDER="13" O_E="0.0" SE="0.15984967157213223" STUDY_ID="STD-Gringeri-2011" TOTAL_1="8" TOTAL_2="10" VAR="0.025551917501718542" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.3113137935414541" CI_START="-0.012371994599655045" EFFECT_SIZE="0.14947089947089953" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 08:23:40 +0000" MODIFIED_BY="Alfonso Iorio" ORDER="14" O_E="0.0" SE="0.08257442246242822" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="28" TOTAL_2="27" VAR="0.006818535245003569" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-08 15:59:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Secondary prophylaxis</NAME>
<DICH_DATA CI_END="0.6999188105136664" CI_START="-0.06744017803503399" EFFECT_SIZE="0.3162393162393162" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 08:25:19 +0000" MODIFIED_BY="Alfonso Iorio" ORDER="21" O_E="0.0" SE="0.1957584411248192" STUDY_ID="STD-Gringeri-2011" TOTAL_1="13" TOTAL_2="9" VAR="0.038321367271619305" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2011-07-20 11:45:06 +0100" MODIFIED_BY="Tracey Remmington" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="49.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life</NAME>
<GROUP_LABEL_1>On demand</GROUP_LABEL_1>
<GROUP_LABEL_2>Prophylaxis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours on demand</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prophylaxis</GRAPH_LABEL_2>
<CONT_DATA CI_END="43.15759581270236" CI_START="22.302404187297647" EFFECT_SIZE="32.730000000000004" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="11.27" MODIFIED="2011-02-21 17:56:44 +0000" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="22.6" SD_2="8.7" SE="5.320299707011916" STUDY_ID="STD-Gringeri-2011" TOTAL_1="21" TOTAL_2="19" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.24102921394156024" CI_END="6.319310679658815" CI_START="4.22772262520768" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.273516652433248" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2011-07-20 11:45:50 +0100" MODIFIED_BY="Tracey Remmington" NO="5" P_CHI2="0.6234637762231793" P_Q="1.0" P_Z="4.9182805443984096E-23" Q="0.0" RANDOM="NO" SCALE="7.8" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="9.883306312297428">
<NAME>Factor concentrate usage [x1000 IU]</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>On demand</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours on demand</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prophylaxis</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.788266508335454" CI_START="2.9537334916645466" EFFECT_SIZE="4.871" ESTIMABLE="YES" MEAN_1="8.852" MEAN_2="3.981" MODIFIED="2011-02-21 21:54:59 +0000" MODIFIED_BY="[Empty name]" ORDER="35" SD_1="3.774" SD_2="2.301" SE="0.9782151730636927" STUDY_ID="STD-Gringeri-2011" TOTAL_1="21" TOTAL_2="19" WEIGHT="29.75276571845585"/>
<CONT_DATA CI_END="6.691761387380414" CI_START="4.196238612619588" EFFECT_SIZE="5.444000000000001" ESTIMABLE="YES" MEAN_1="8.018" MEAN_2="2.574" MODIFIED="2011-02-21 21:55:20 +0000" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="3.419" SD_2="1.1488" SE="0.6366246508724626" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="32" TOTAL_2="33" WEIGHT="70.24723428154415"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.152104843740335" CI_END="0.09345300635813009" CI_START="-0.03147504747680299" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RD" EFFECT_SIZE="0.030988979440663544" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="30.09051028696678" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-1.02940672292351" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5087927261352418" METHOD="MH" MODIFIED="2011-07-20 11:47:25 +0100" MODIFIED_BY="Tracey Remmington" NO="6" P_CHI2="0.20957175208118273" P_Q="0.6179763153411422" P_Z="0.33087338815645817" Q="1.7860459984382062" RANDOM="YES" SCALE="0.42" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.002537828026751711" TOTALS="SUB" TOTAL_1="164" TOTAL_2="154" WEIGHT="400.0" Z="0.9723561963368879">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>On demand</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours on demand</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.042898685917588" CI_END="0.42151350339438426" CI_START="-0.1350199318851279" DF="1" EFFECT_SIZE="0.14324678575462818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="75.26527183371559" ID="CMP-002.06.01" LOG_CI_END="-0.37518850797700454" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.8439151141751597" MODIFIED="2010-10-22 10:52:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04435765844149575" P_Z="0.3129963247731483" STUDIES="2" TAU2="0.030351775993062206" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.00000000000001" Z="1.008954801930953">
<NAME>Infections (All patients)</NAME>
<DICH_DATA CI_END="0.4882708577681475" CI_START="0.08315771366042388" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-09 15:55:46 +0000" MODIFIED_BY="Emanuela Marchesini" ORDER="15" O_E="0.0" SE="0.10334708885040858" STUDY_ID="STD-Gringeri-2011" TOTAL_1="21" TOTAL_2="19" VAR="0.010680620773854245" WEIGHT="49.124649289768676"/>
<DICH_DATA CI_END="0.1943748606700642" CI_START="-0.18301122430642786" EFFECT_SIZE="0.005681818181818177" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-26 13:44:27 +0100" MODIFIED_BY="Alfonso Iorio" ORDER="16" O_E="0.0" SE="0.09627372950555861" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.009268630992909466" WEIGHT="50.87535071023134"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05730583001218964" CI_END="0.14672313740055765" CI_START="-0.03124018848408297" DF="1" EFFECT_SIZE="0.05774147445823734" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="-0.8335013949975155" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.23851213038082" MODIFIED="2010-10-22 11:39:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8108060067891675" P_Z="0.20342691515078082" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.00000000000001" Z="1.271848677696038">
<NAME>Inhibitors (All patients)</NAME>
<DICH_DATA CI_END="0.24116523265565026" CI_START="-0.16597726273083824" EFFECT_SIZE="0.03759398496240601" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-26 13:50:47 +0100" MODIFIED_BY="Alfonso Iorio" ORDER="17" O_E="0.0" SE="0.10386479001603513" STUDY_ID="STD-Gringeri-2011" TOTAL_1="21" TOTAL_2="19" VAR="0.010787894605075071" WEIGHT="19.105928967681052"/>
<DICH_DATA CI_END="0.16143322625120954" CI_START="-0.036433226251209525" EFFECT_SIZE="0.0625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-26 13:49:29 +0100" MODIFIED_BY="Alfonso Iorio" ORDER="18" O_E="0.0" SE="0.050477063370338526" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.0025479339264931713" WEIGHT="80.89407103231896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.1899735924600273" CI_START="-0.2561804890117514" DF="0" EFFECT_SIZE="-0.03310344827586206" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="-0.7213067645522315" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-10-22 10:52:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7711673837077521" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="25" WEIGHT="100.0" Z="0.29084824763114153">
<NAME>Infections (Patients with CVC)</NAME>
<DICH_DATA CI_END="0.1899735924600273" CI_START="-0.2561804890117514" EFFECT_SIZE="-0.03310344827586206" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-10 10:34:40 +0100" MODIFIED_BY="Emanuela Marchesini" ORDER="20" O_E="0.0" SE="0.11381690811437994" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="29" TOTAL_2="25" VAR="0.012954288572717208" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8029060105632546E-34" CI_END="0.09602437765419261" CI_START="-0.10705886041281329" DF="0" EFFECT_SIZE="-0.005517241379310346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="100.0" ID="CMP-002.06.04" LOG_CI_END="-1.0176184988696422" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-07-20 11:06:35 +0100" MODIFIED_BY="Tracey Remmington" NO="4" P_CHI2="0.0" P_Z="0.9151902498588405" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="25" WEIGHT="100.0" Z="0.10649420897941858">
<NAME>Inhibitors (Patients with CVC)</NAME>
<DICH_DATA CI_END="0.09602437765419261" CI_START="-0.10705886041281329" EFFECT_SIZE="-0.005517241379310346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-20 11:06:35 +0100" MODIFIED_BY="Tracey Remmington" ORDER="23" O_E="0.0" SE="0.05180790046880977" STUDY_ID="STD-Manco_x002d_Johnson-2007" TOTAL_1="29" TOTAL_2="25" VAR="0.0026840585509861" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-07-20 11:24:23 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<NAME>Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate (post-infusion level)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-07-20 11:24:23 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="94.99" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="4" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Bleed frequency</NAME>
<GROUP_LABEL_1>2x/wk 0.30 IU/mL</GROUP_LABEL_1>
<GROUP_LABEL_2>2x/wk 0.15 IU/mL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2x/wk 0.30IU/mL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2x/wk 0.15IU/mL</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate difference</EFFECT_MEASURE>
<IV_DATA CI_END="6.935379945539732" CI_START="-17.01537994553973" EFFECT_SIZE="-5.04" ESTIMABLE="YES" ESTIMATE="-5.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9169" SE="6.11" STUDY_ID="STD-Aronstam-1977" TOTAL_1="4" TOTAL_2="4" WEIGHT="0.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-07-20 11:52:20 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<NAME>Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-27 14:27:01 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.305310044098594" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Bleed frequency</NAME>
<GROUP_LABEL_1>Pharmacokinetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pharmacokinetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.052678030569433" CI_START="-1.338478030569433" EFFECT_SIZE="-0.1429" ESTIMABLE="YES" ESTIMATE="-0.1429" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9171" SE="0.61" STUDY_ID="STD-Carlsson-1997" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2011-07-20 11:52:20 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.41" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="14" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Clotting factor concentrate usage [x1000]</NAME>
<GROUP_LABEL_1>Fixed dose proph</GROUP_LABEL_1>
<GROUP_LABEL_2>PK adjusted proph</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PK adjusted</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fixed dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.181857063863982" CI_START="1.4181429361360198" EFFECT_SIZE="3.3000000000000007" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="7.0" MODIFIED="2011-07-10 15:39:02 +0100" MODIFIED_BY="Alfonso Iorio" ORDER="23" SD_1="2.5" SD_2="2.58" SE="0.9601487979921208" STUDY_ID="STD-Carlsson-1997" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-05-27 14:27:09 +0100" MODIFIED_BY="Tracey Remmington" NO="5">
<NAME>Standard prophylaxis versus alternative prophylaxis (factor IX concentrate)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-27 14:27:09 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.648317649604003" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Bleed frequency</NAME>
<GROUP_LABEL_1>Bi-weekly 0.075IU/mL</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly 0.15IU/mL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours bi-weekly</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate difference</EFFECT_MEASURE>
<IV_DATA CI_END="-1.1048403373151388" CI_START="-5.495159662684861" EFFECT_SIZE="-3.3" ESTIMABLE="YES" ESTIMATE="-3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9170" SE="1.12" STUDY_ID="STD-Morfini-1976" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-07-20 13:22:00 +0100" MODIFIED_BY="Tracey Remmington">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-07-20 13:22:00 +0100" MODIFIED_BY="Tracey Remmington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-07-20 13:22:00 +0100" MODIFIED_BY="Tracey Remmington" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-05-19 14:10:50 +0100" MODIFIED_BY="Tracey Remmington">
<APPENDIX ID="APP-01" MODIFIED="2011-05-19 14:10:50 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<TITLE MODIFIED="2011-04-07 14:22:31 +0100" MODIFIED_BY="[Empty name]">Search strategies for current version of the review</TITLE>
<APPENDIX_BODY MODIFIED="2011-05-19 14:10:50 +0100" MODIFIED_BY="Tracey Remmington">
<TABLE COLS="2" ROWS="4">
<TR>
<TD>
<P>Database</P>
</TD>
<TD>
<P>Strategy</P>
</TD>
</TR>
<TR>
<TD>
<P>The Cochrane Central Register of Controlled Trials (CENTRAL)</P>
<P>Issue 4, 2010</P>
</TD>
<TD>
<P>#1 hemophilia<BR/>#2 haemophilia<BR/>#3 (#1 or #2)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE (Ovid)</P>
<P>2003 -14th Feb 2011</P>
</TD>
<TD>
<P>1     (inherit$ or heredit$ or congenital or severe).mp. (778243)</P>
<P>2     (blood adj5 disorder).mp. (1569)</P>
<P>3     (hemophili$ or haemophili$).mp. (19425)</P>
<P>4     bleed$.mp. (107960)</P>
<P>5     exp blood coagulation disorders/ (72445)</P>
<P>6     exp coagulation protein disorders/ (25400)</P>
<P>7     coagulation factor deficien$.mp. (180)</P>
<P>8     christmas disease$.mp. (215)</P>
<P>9     or/2-8 (174132)</P>
<P>10     1 and 9 (25842)</P>
<P>11     (factor adj3 concentrat$).mp. (7116)</P>
<P>12     plasma.mp. (594094)</P>
<P>13     cryoprecipitat$.mp. (1977)</P>
<P>14     lyophilized plasma.mp. (76)</P>
<P>15     (recombinant adj3 factor$).mp. (6770)</P>
<P>16     or/11-15 (605334)</P>
<P>17     prevent$.mp. (730741)</P>
<P>18     exp primary prevention/ (95951)</P>
<P>19     prophyla$.mp. (104804)</P>
<P>20     or/17-19 (878004)</P>
<P>21     ("factor 8" or "Factor 8" or "f viii" or "f VIII" or "F VIII" or fviii or fVIII or FVIII or f-viii or f-VIII or F-VIII or "factor viii" or "factor VIII" or "Factor VIII" or "factor 9" or "Factor 9" or "f ix" or "f IX" or "F IX" or fix or fIX or FIX or f-ix or f-IX or F-IX or "factor ix" or "factor IX" or "Factor IX").mp. (27545)</P>
<P>22     and/10,16,20-21 (279)</P>
<P>23     22 (279)</P>
<P>24     limit 23 to yr="2003 -Current" (145)</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE (Ovid)</P>
<P>2003 - 14th Feb 2011</P>
</TD>
<TD>
<P>1     (hemophili$ or haemophili$).mp. (24152)</P>
<P>2     blood disease/ (4208)</P>
<P>3     blood disorder$.mp. (711)</P>
<P>4     blood clotting disorder/ (19027)</P>
<P>5     "blood coagulation disorder".mp. (65)</P>
<P>6     "coagulation protein disorder".mp. (0)</P>
<P>7     exp blood clotting factor deficiency/ (33506)</P>
<P>8     coagulation factor deficien$.mp. (255)</P>
<P>9     exp congenital blood clotting disorder/ (27042)</P>
<P>10     christmas disease$.mp. (194)</P>
<P>11     bleed$.mp. (232718)</P>
<P>12     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (275630)</P>
<P>13     (inherit$ or heredit$ or congenital or severe).mp. (1157640)</P>
<P>14     12 and 13 (39178)</P>
<P>15     exp blood clotting factor concentrate/ (531)</P>
<P>16     coagulation factor deficien$.mp. (255)</P>
<P>17     fresh frozen plasma.mp. (7327)</P>
<P>18     exp plasma/ (51835)</P>
<P>19     plasma.mp. (696927)</P>
<P>20     cryoprecipitat$.mp. (3260)</P>
<P>21     lyophilized plasma.mp. (97)</P>
<P>22     exp recombinant blood clotting factor 8/ (1707)</P>
<P>23     exp recombinant blood clotting factor 9/ (445)</P>
<P>24     recombinant factor$.mp. (2207)</P>
<P>25     15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 (701280)</P>
<P>26     exp prevention/ (731271)</P>
<P>27     exp primary prevention/ (19405)</P>
<P>28     prevent$.mp. (1008998)</P>
<P>29     exp prophylaxis/ (535291)</P>
<P>30     prophyla$.mp. (156872)</P>
<P>31     26 or 27 or 28 or 29 or 30 (1524847)</P>
<P>32     ("factor 8" or "Factor 8" or "f viii" or "f VIII" or "F VIII" or fviii or fVIII or FVIII or f-viii or f-VIII or F-VIII or "factor viii" or "factor VIII" or "Factor VIII" or "factor 9" or "Factor 9" or "f ix" or "f IX" or "F IX" or fix or fIX or FIX or f-ix or f-IX or F-IX or "factor ix" or "factor IX" or "Factor IX").mp. (35580)</P>
<P>33     exp blood clotting factor 8/ (15240)</P>
<P>34     exp blood clotting factor 9/ (5758)</P>
<P>35     32 or 33 or 34 (35580)</P>
<P>36     14 and 25 and 31 and 35 (473)</P>
<P>37     limit 36 to yr="2003 -Current" (329)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-04-07 14:34:20 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-04-07 14:22:42 +0100" MODIFIED_BY="[Empty name]">Search strategies for previous versions of the review</TITLE>
<APPENDIX_BODY MODIFIED="2011-04-07 14:34:20 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TD>
<P>Database</P>
</TD>
<TD>
<P>Strategy</P>
</TD>
</TR>
<TR>
<TD>
<P>The Cochrane Central </P>
<P>Register of Controlled </P>
<P>Trials (CENTRAL)</P>
<P>1948-2003</P>
</TD>
<TD>
<P>#1 Therapeutics<BR/>#2 Intervention studies<BR/>#3 (therap* or intervention* or treat*)<BR/>#4 (#1 or #2 or #3)<BR/>#51 hemophilia<BR/>#62 haemophilia<BR/>#73 (#51 or #62)<BR/>#8 (#4 and #7)</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE (Ovid)</P>
<P>Jan 1966-May 2003</P>
</TD>
<TD>
<P>1. (inherit$ or heredit$ or congenital).mp.<BR/>2. (blood adj5 disorder).mp.<BR/>3. (hemophili$ or haemophili$).mp.<BR/>4. bleed$.mp.<BR/>5. exp blood coagulation disorders/<BR/>6. exp coagulation protein disorders/<BR/>7. coagulation factor deficien$.mp.<BR/>8. christmas disease$.mp.<BR/>9. or/2-8<BR/>10. 1 and 9<BR/>11. (factor adj3 concentrat$).mp.<BR/>12. plasma.mp.<BR/>13. cryoprecipitat$.mp.<BR/>14. lyophilized plasma.mp.<BR/>15. (recombinant adj3 factor$).mp.<BR/>16. or/11-15<BR/>17. prevent$.mp.<BR/>18. exp primary prevention/<BR/>19. prophyla$.mp.<BR/>20. or/17-19<BR/>21. ("factor 8" or "f viii" or fviii or "factor viii" or "factor 9" or "f ix" or fix or "factor ix").mp.<BR/>22. and/10,16,20-21<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE (Ovid)</P>
<P>1988- May 2003</P>
</TD>
<TD>
<P>1. (hemophili$ or haemophili$).mp.<BR/>2. blood disease/<BR/>3. blood disorder$.mp.<BR/>4. blood disorder$.mp.<BR/>5. blood clotting disorder/<BR/>6. "blood coagulation disorder".mp.<BR/>7. "coagulation protein disorder".mp.<BR/>8. exp blood clotting factor deficiency/<BR/>9. coagulation factor deficien$.mp.<BR/>10. exp congenital blood clotting disorder/<BR/>11. christmas disease$.mp.<BR/>12. bleed$.mp.<BR/>13. or/1-12<BR/>14. (inherit$ or heredit$ or congenital).mp.<BR/>15. 13 and 14<BR/>16. exp blood clotting factor concentrate/<BR/>17. coagulation factor deficien$.mp.<BR/>18. fresh frozen plasma.mp.<BR/>19. exp plasma/<BR/>20. plasma.mp.<BR/>21. cryoprecipitat$.mp.<BR/>22. lyophilized plasma.mp.<BR/>23. exp recombinant blood clotting factor 8/<BR/>24. exp recombinant blood clotting factor 9/<BR/>25. recombinant factor$.mp.<BR/>26. or/16-25<BR/>27. exp prevention/<BR/>28. exp primary prevention/<BR/>29. prevent$.mp.<BR/>30. exp prophylaxis/<BR/>31. prophyla$.mp.<BR/>32. or/27-31<BR/>33. ("factor 8" or "f viii" or fviii or "factor viii" or "factor 9" or "f ix" or fix or "factor ix").mp.<BR/>34. exp blood clotting factor 8/<BR/>35. exp blood clotting factor 9/<BR/>36. or/33-35<BR/>37. and/15,26,32,36<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>